JPH0226988B2 - - Google Patents
Info
- Publication number
- JPH0226988B2 JPH0226988B2 JP61152166A JP15216686A JPH0226988B2 JP H0226988 B2 JPH0226988 B2 JP H0226988B2 JP 61152166 A JP61152166 A JP 61152166A JP 15216686 A JP15216686 A JP 15216686A JP H0226988 B2 JPH0226988 B2 JP H0226988B2
- Authority
- JP
- Japan
- Prior art keywords
- oxirane
- body fluid
- fluid component
- group
- heterocyclic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001124 body fluid Anatomy 0.000 claims description 62
- 239000010839 body fluid Substances 0.000 claims description 62
- 238000000926 separation method Methods 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 34
- 239000011324 bead Substances 0.000 claims description 33
- 150000002391 heterocyclic compounds Chemical group 0.000 claims description 26
- 125000000466 oxiranyl group Chemical group 0.000 claims description 25
- 239000000178 monomer Substances 0.000 claims description 18
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 2
- 239000003463 adsorbent Substances 0.000 description 33
- 238000001179 sorption measurement Methods 0.000 description 26
- 239000000126 substance Substances 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- 230000001717 pathogenic effect Effects 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000000746 purification Methods 0.000 description 14
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 14
- 229960001544 sulfathiazole Drugs 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- -1 polylysine Chemical class 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000007142 ring opening reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012052 hydrophilic carrier Substances 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- WTEICVOERQQONI-UHFFFAOYSA-N [C].C1CO1 Chemical group [C].C1CO1 WTEICVOERQQONI-UHFFFAOYSA-N 0.000 description 2
- HKNSIVFWRXBWCK-UHFFFAOYSA-N [N].NC1=CC=CC=C1 Chemical compound [N].NC1=CC=CC=C1 HKNSIVFWRXBWCK-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- TURITJIWSQEMDB-UHFFFAOYSA-N 2-methyl-n-[(2-methylprop-2-enoylamino)methyl]prop-2-enamide Chemical compound CC(=C)C(=O)NCNC(=O)C(C)=C TURITJIWSQEMDB-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- HAUGRYOERYOXHX-UHFFFAOYSA-N Alloxazine Chemical class C1=CC=C2N=C(C(=O)NC(=O)N3)C3=NC2=C1 HAUGRYOERYOXHX-UHFFFAOYSA-N 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000287826 Gallus Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229940106705 chlorophyll Drugs 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000004863 dithiolanes Chemical class 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001914 gastric parietal cell Anatomy 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- JRIDTVOTHRSTJZ-UHFFFAOYSA-N n'-cyclohexyl-n-(2-morpholin-4-ylethyl)methanediimine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1CCCCC1N=C=NCCN1CCOCC1 JRIDTVOTHRSTJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- PYOZTOXFQNWBIS-UHFFFAOYSA-N phenol;sodium Chemical compound [Na].OC1=CC=CC=C1 PYOZTOXFQNWBIS-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- KJVQYDYPDFFJMP-UHFFFAOYSA-N sulfamethylthiazole Chemical compound CC1=CSC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 KJVQYDYPDFFJMP-UHFFFAOYSA-N 0.000 description 1
- 229950005939 sulfamethylthiazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
çºæã®èæ¯
ïŒæè¡åéïŒ
æ¬çºæã¯ãè¡æ¶²çã®äœæ¶²ããç¹å®ã®æåãåžç
åé¢ããäœæ¶²æååé¢æãšããããçšããäœæ¶²æ
ååé¢è£ 眮ã«é¢ããã ïŒå è¡æè¡ããã³ãã®åé¡ç¹ïŒ è¿å¹Žãäœæ¶²äžã®ç¹å®æåãé節ãªçç¶ãæ¹èµ·ã
ãçŸæ£ã®æ²»çæ³ãšããŠãè¡æŒ¿äº€æçæ³ãè¡ãªãã
ãŠããããã®çæ³ã¯ç å ç©è³ªã®éæãå°é£ãªå Žå
ã«ç¹ã«å¹æçã§ãéççç¡åçãé¢ç¯ãªãŠããã
çŽ ææ§çŒç¡çã®èªå·±å ç«çŸæ£ã糞çäœè çãæ°ç®¡
æ¯åæ¯ãå€çºæ§ç¥çµççã®å ç«é¢é£çŸæ£ãèåšç§»
æ€ã«äŒŽãæ絶åå¿ãèäžå šãé«è¡å§ãççŸæ£ãã
ã®ä»ã«å¯ŸããŠé©çšãããŠããããã®ãã¡èªå·±å ç«
çŸæ£ãšã¯ãèªå·±ã®çŽ°èãçµç¹ã®ãã€æåã«å¯ŸããŠ
äœæ¶²æ§ãããã¯çŽ°èæ§ã®å ç«å¿çããããããã
ã«ãã€ãŠåœ¢æãããèªå·±ã«å¯Ÿããæäœãåå ãšãª
ã€ãŠçºçããçŸæ£ãããã ããããè¡æŒ¿äº€æçæ³ã¯è¡æŒ¿æåã®å šãŠãç¡å·®
å¥ã«é€å»ãããããç å ç©è³ªä»¥å€ã«è¡æŒ¿ã®æçšæ
åããåªå€±ããŠããŸãåé¡ããããå ããŠãè£å
液ãšããŠã®è¡æŒ¿ãè¡æŒ¿è£œå€ã®äžè¶³ãè¡æž èçãã¢
ã¬ã«ã®ãŒçã®å䜵ãšãã€ãå€ãã®åé¡ãææãã
ãŠããããããããèªå·±ã®è¡æŒ¿ãæµåããåŸã«å
茞泚ããæ¹æ³ãå³ã¡ãäœå€åŸªç°æ¶²æµåçæ³ãæãŸ
ãããšãããŠããããã®å Žåãèªå·±ã®è¡æ¶²ããç
å ç©è³ªãå åäžã€éžæçã«é€å»ããæ²»çç®çãé
æãããšå ±ã«äœèçœè¡çãé²æ¢ããããšãå¿ èŠ
ã§ããã®ããã®æµåæãšããŠåŸæ¥æ¬¡ã®ãããªåžç
æãç¥ãããŠããã ã» å€åæ§æš¹èïŒäŸãã°RošhmïŒHaas瀟補ã®å
ååãã¢ã³ããŒã©ã€ãXADâïŒãç ã» ã€ãªã³äº€æäœïŒäŸãã°ã«ã«ããã·ã¡ãã«ã»ã«
ããŒã¹ããžãšãã«ã¢ãããšãã«ã¢ã¬ããŒã¹çïŒ ã» ç¡æ©å€åäœïŒäŸãã°å€å質ã¬ã«ã¹ãã»ã©ãã
ã¯çïŒ ã» ã¢ãã€ããã€ãŒåžçæ ããããå€åæ§æš¹èãã€ãªã³äº€æäœã¯åžçèœã
å°ããããããåžçç¹ç°æ§ãäœãããäœæ¶²äžã®ã¢
ã«ããã³ããåžçããããã®çµæããããè¡æ¶²æµ
åæãšããŠåèšçæ³ã«é©çšãããšæ²»çå¹æãäžå
åãªã§ã ãã§ãªããäœèçœè¡çã«ç¹æã®æµžéå§ç°
åžžãæ¥ãããŠæµ®è «ãçããçãå®å šæ§ã«åé¡ãã
ãããŸããç¡æ©å€åäœã¯åžçèœãåžçç¹æ§ã«ã€ã
ãŠã¯æ¯èŒçè¯å¥œã§ããããæªã å®çšçã«ã¯äžåå
ã§ããã ããã«å¯Ÿããã¢ãã€ããã€ãŒåžçæã¯åªããåž
çèœããã³åžçç¹ç°æ§ãæããè¡æ¶²æµåæãšããŠ
ææèŠãããŠããããã®ã¿ã€ãã®åžçæã¯ãã®åž
çäœçšã®çžéãããçç©åŠçã¢ãã€ããã€ãŒåžç
æãšç©çååŠçã¢ãã€ããã€ãŒåžçæãšã«åé¡ã
ãããã®äžè¬çç¹åŸŽãšãã®åé¡ç¹ã説æããã°æ¬¡
ã®éãã§ããã ãŸãçç©åŠçã¢ãã€ããã€ãŒåžçæã¯æåæäœ
çµåãè£äœçµåãFcçµåçã®çç©åŠççžäºäœçš
ã§è¡æ¶²äžã®ç å ç©è³ªãšçµåãããããåžçããã
ã®ã§ãåžçç¹ç°æ§ã«æ¥µããŠåªããŠããããããã
ãã®å€ãã¯DNAãæLDLæäœããããã€ã³ïŒ¡ç
ã®çç掻æ§é«ååããªã¬ã³ãïŒç®çãšããç å ç©
質ãšèŠªåæ§ããã€ç©è³ªïŒãšããŠçšãããããåæ
ãé«äŸ¡ã§äžã€ç¢ºä¿ãå°é£ã§ããåé¡ãããããŸ
ãããªã¬ã³ãã®å®å®æ§ãä¹ãããããåžçæãã
ããå å¡«ããã«ã©ã ã®è£œé ãæ» èã貯èµãéæ¬ã
ä¿ç®¡ã«éããŠæŽ»æ§ãä¿æããã®ãé£ãããå ã
ãŠããªã¬ã³ããæ¬æ¥çã«çç掻æ§ç©è³ªã§ããã
ãããããè¡æ¶²ãšæ¥è§Šããå Žåã«ææã®èŠªååã
çºæ®ããã«æ¢ãŸãããæ¬æ¥ã®ççäœçšãçºçŸããŠ
å¯äœçšãçããããšãèæ ®ããªããã°ãªããªãã
ãããããªã¬ã³ãã¯ç°çš®èçœã§ãããããããã
åžçææ äœããéé¢ããŠæº¶åºããå Žåããã®æå
æ§ã«ããå¯äœçšãçºçããããšã«ãªãã ããã«å¯Ÿããç©çååŠçã¢ãã€ããã€ãŒåžçæ
ã¯éé»çµåãçæ°Žçµåçãç©ççãŸãã¯ååŠççž
äºäœçšã§è¡æ¶²äžã®ç å ç©è³ªãšçµåãããããåžç
åé¢ããŠé€å»ãããã®ã§ããããã®å Žåã®ãªã¬ã³
ããšããŠã¯ããªãªãžã³ãã¡ãã«åã¢ã«ããã³ãã
ãªãããã¢ã³ãããšãã«ã¢ã©ãã³çã®åæç©ãçš
ããããšãã§ããããã®ãã倧é補é ãå¯èœã§äŸ¡
æ Œãæ¯èŒçå®ãã掻æ§ãå®å®ã§ããå©ç¹ãæããŠ
ããããŸãè¡æ¶²ãšæ¥è§Šããå Žåã®å®å šæ§ã«ã€ããŠ
ãäžè¬ã«åªãããã®ãå€ããããåèšçŸæ£æ²»çã®
ããã®äœå€åŸªç°äœæ¶²æµåçæ³ã«çšããæµåæãšã
ãŠæãæåŸ ãããããŠãããæŽã«ããã®äœçšãã
ã³äŸ¡æ ŒããããŠãäžèšçæ³ã®ããã®è¡æ¶²æµåæãš
ããŠã®ã¿ãªãããå ç«ã°ãããªã³ãå ç«è€åäœã
ãã³å ç«é¢é£å¯æº¶æ§å åçã®äœæ¶²ç¹å®æåã®åé¢
粟補ããŸãã¯ãããæåã®æ€æ»ã«ãçšéãæåŸ ã
ããããã®åé¡ã«å±ããåžçæã§åŸæ¥ç¥ãããŠã
ããã®ãæããã°æ¬¡ã®éãã§ããã ã«ã«ããã·ã«åºãŸãã¯ã¹ã«ãã³é žåºãè¡šé¢ã«
æããå€åäœïŒç¹éæ56â147710ãå57â
56038ãå57â75141ãå57â170263ãå57â
197294ïŒ çæ°Žæ§ã¢ããé žãçµåãããŠãã芪氎æ§æ äœ
ïŒç¹éæ57â122875ãå58â15924ãå58â
165859ãå58â165861ïŒ å€æ§å ç«ã°ãããªã³ïŒlgGïŒãçµåãããŠã
ã芪氎æ§æ äœïŒç¹éæ57â77624ãå57â
77625ãå57â156035ïŒ ã¡ãã«åã¢ã«ããã³ãçµåãããŠããå€åäœ
ïŒç¹éæ55â120875ãå55â125872ïŒ ç³ãçµåãããŠãã芪氎æ§æ äœïŒç¹éæ57â
134164ãå58â133257ïŒ ããªã³å¡©åºãŸãã¯ããªããžã³å¡©åºãæãã¯ç³
çé žãçµåãããŠããå€åäœïŒç¹éæ57â
192560ãå58â61752ãå58â98142ïŒ ãããããããåŸæ¥ã®ç©çååŠçã¢ãã€ããã€
ãŒåžçæããåèšäœå€åŸªç°æ¶²æµåçæ³ã«ããèªå·±
å ç«çŸæ£çã®æ²»çã«ã¯æªã å åãšã¯ããããæŽã«
é«ãå¹çããã³ç¹ç°æ§ã§ç å ç©è³ªãé€å»ããããš
ãã§ãããŸãäœæ¶²ã«å¯Ÿããæªåœ±é¿ã®å°ãªãæµåæ
ãæãŸããŠããã çºæã®ç®ç æ¬çºæã¯äžèšäºæ ã«éã¿ãŠãªããããã®ã§ãã
ã®ç®çã¯è¡æ¶²ããªã³ã液ãè ¹æ°Žçã®äœæ¶²äžã«å«ãŸ
ããç¹å®æåãé«å¹çãã€é«ãç¹ç°æ§ã§åžçåé¢
ã§ãããšå ±ã«ã掻æ§ãå®å®ã§æ» èæäœãä¿ç®¡ã容
æãªäœæ¶²æååé¢æã䞊ã³ã«ãããçšããäœæ¶²æ
ååé¢è£ 眮ãæäŸããããšã§ããã æ¬çºæã®ç¬¬äžã®ç®çã§ããäœæ¶²æååé¢æã¯ã
ãªãã·ã©ã³åºãæããäžé£œåã®ã©ãžã«ã«éåæ§ã¢
ãããŒåã³æ¶æ©æ§ã¢ãããŒãå«ãã¢ãããŒæ··åç©
ãéåããŠåŸãã¢ã¯ãªã«ç³»ããªããŒã®ãã¡ããªã
ã·ã©ã³åºå«æéã也ç¥ééïŒïœåœã0.1ã10mmol
ã§ãããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã«ãè€çŽ ç°åŒ
ååç©ãçµåãããããšã«ãã€ãŠåŸãããããã®
éãåèšè€çŽ ç°åŒååç©ã®è€çŽ ç°ä»¥å€ã®ååãå
èšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºè¡šé¢ã«é²åºãããª
ãã·ã©ã³åºãæ§æããäžæ¹ã®ççŽ ã«å ±æçµåãã
ããšå ±ã«ãåèšãªãã·ã©ã³åºã¯éç°ããããã®é ž
çŽ ååã¯æ°Žé žåºãšããŠä»æ¹ã®ççŽ ååã«å ±æçµå
ãããããšã«ãªãã æ¬çºæã®ç¬¬äºã®ç®çã§ããäœæ¶²æååé¢è£ 眮
ã¯ãçžäºã«é£éããäœæ¶²å°å ¥å£ããã³äœæ¶²å°åºå£
ãæãã容åšå ã«ãäžèšã®äœæ¶²æååé¢æãå å¡«
ããããšã«ãã€ãŠåŸããããå¿ èŠã«å¿ããäœæ¶²åŸª
ç°ãã³ãçã®èŠçŽ ãä»å ããã æ¬çºæã¯èªå·±å ç«çŸæ£çã®æ²»çãç®çãšããäœ
å€åŸªç°äœæ¶²æµåçæ³ã«ãããŠãç¹ã«å¥œé©ã«çšãã
ããšãã§ããã çºæã®å ·äœç説æ æ¬çºæã®äœæ¶²æååé¢æã¯ãæ¢è¿°ããç©çååŠ
çã¢ãã€ããã€ãŒåžçæã«å±ããããã®å¯Ÿè±¡ãšã
ã被åžçç©è³ªã¯äœæ¶²äžã®èçœè³ªã§ãããããã詳
现ã«èª¬æããã°æ¬¡ã®éãã§ãããå³ã¡ãéåžžã®å
ç«ã°ãããªã³ïŒïŒ¡ïŒïŒ€ïŒïŒ¥ïŒïŒ§ïŒïŒïŒãåçš®èªå·±
æäœãå ç«ã°ãããªã³çžäºéãŸãã¯å ç«ã°ãããª
ã³ãšä»ã®ç©è³ªïŒç¹ã«æäœïŒãšã®è€åç©ãè£äœãã
ã€ããªããŒã²ã³ãå¯æº¶æ§ãã€ããªã³ãäœå¯åºŠãªã
ãããã€ã³ãç现èå¢æ®å åãå ç«é¢é£å¯æº¶æ§å
åïŒIRAïŒlmmunoâregulatory αâglobulinïŒ
ã»ã«æé·å åïŒTCGFïŒïŒŽâcell growth
factorïŒãGSFïŒGrowth soluble factorïŒãSSF
ïŒSuppresor soluble factorïŒãTRFïŒïŒŽâcell
replacing factorïŒãKHFïŒKiller cell helper
factorïŒãLSFïŒLymphocyteâstimulating
factorïŒãCIFïŒCompetenceâinducing factorïŒã
TDFïŒThymocytoâdiffer entiation factorïŒã
ã€ã³ã¿ãŒãã€ãã³çã§ããããã®ãã¡ãèªå·±æ
äœã®äŸãšããŠã¯ã现èè¡šé¢æäœãèå£çŽ°èãã¯ã
ãŸãŒã æäœãå¯è ç®è³ªçŽ°å¯è³ªæäœçã®èåšç¹ç°å
ïŒç¬¬çŸ€ïŒãã¢ã»ãã«ã³ãªã³ã¬ã»ãã¿ãŒã«å¯Ÿããæ
äœãèµ€è¡çæäœãå¹³æ¡æ»çæäœãã€ã³ã·ãŠãªã³ã¬
ã»ãã¿ãŒæäœçã®äžéåïŒç¬¬çŸ€ïŒãDNAæäœã
ååºå åæäœãææ žæäœãælgGæäœçã®èåšé
ç¹ç°åïŒç¬¬çŸ€ïŒãæããããããªããæ¬çºæã«
ãããåé¢å¯Ÿè±¡ã§ãããããç å èçœç©è³ªã¯ãäœ
ããäœæ¶²èçœåç»ã®ãã¡ã®ã°ãããªã³åç»ã«å«ãŸ
ããŠããã æ¬çºæã®äœæ¶²æååé¢æã¯ãªãã·ã©ã³âã¢ã¯ãª
ã«ããŒãºãäžæº¶æ§æ äœãšãããã®è¡šé¢ã«è€çŽ ç°åŒ
ååç©ãçµåãããã®ã§ãããããã§äžæº¶æ§æ
äœãè€çŽ ç°åŒååç©ããã³ãããã®çµåæ¹æ³çã«
ã€ããŠå€«ã 説æããã äžæº¶æ§æ äœãšããŠçšãããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã¯ãã¡ã¿ã¯ãªã«é žã°ãªã·ãžã«ãŸãã¯ã¢ãªã«
ã°ãªã·ãžã«ãšãŒãã«ãã¡ã¿ã¯ãªã«ã¢ãããã¡ãã¬
ã³âãã¹âã¡ã¿ã¯ãªã«ã¢ããã®å ±éåã«ããåŸã
ããããã®è£œæ³ã¯ããŒã ã»ãã¢ã«ã瀟ïŒRošhm
PharmaïŒã«ããé瀺ãããŠããïŒè±åœç¹èš±ç¬¬
1329062å·ããã€ãåœç¹èš±å ¬å第2237316å·ããã€
ãåœç¹èš±ç¬¬2263289å·ïŒããã®ãªãã·ã©ã³âã¢ã¯ãª
ã«ããŒãºã®å ãæ¬çºæã«ãããäžæº¶æ§æ äœãšããŠ
ç¹ã«å¥œé©ã«çšãããããã®ã¯ãæ¶æ©æ§ã¢ãããŒã®
æ¯çãïŒééïŒ ä»¥äžããªãã·ã©ã³åºãæããã©ãž
ã«ã«éåæ§ã¢ãããŒã®æ¯çãïŒã60ééïŒ ã®ã¢ã
ããŒæ··åç©ããåŸããããã®ã§ããããã®ããã«
ç¹ã«å¥œãŸãããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã®äŸãš
ããŠã¯ãããŒã ã»ãã¢ã«ã瀟ããããªã€ããŒã®ã
ããã®åååã§æäŸãããŠãããã®ãæããã
ããããã¯ãåœå ã«ãããŠæšå£åäŒã«ããèŒžå ¥è²©
売ãããŠããã äžèšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã®åœ¢ç¶ã¯çŽ°è
ã«æå·ãäžããããŸãç ããæ¬ ããçãé£ããã
ã«ç圢ãšãããŠãããå¹³åç²åŸã¯ãäœæ¶²ã®æµéã
æµéå§åãèæ ®ãã0.05mmãïŒmmã®ç¯å²ã奜ãŸã
ãã¯0.1mmã0.2mmã®ç¯å²ã®ãã®ãçšãããããå¹³
åç²åŸãæ±ããã«ã¯JISââ8801ã«èŠå®ãããŠ
ãã篩ãçšããŠåçŽããåŸãåçŽã«ã€ããŠã¯äžé
ç²åŸãšäžéç²åŸã®äžéå€ãåœè©²çŽã®ç²åŸãšããã
ããã®ééå¹³åãšããŠå šäœã®å¹³åç²åŸãç®åºã
ãã ãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã¯ãç å ç©è³ªãé«
ãå¹çã§åžçé€å»ããããã«è¡šé¢ç©ã®å€§ããå€å
äœã§ããããšã奜ãŸããããŸãã該å€åäœã®å¹³å
ååŸãå°ãéãããšåžçãããç å ç©è³ªã®éãå°
ãªãã倧ãéãããšå€åäœã®åŒ·åºŠãäœäžãäžã€è¡š
é¢ç©ãæžå°ãããããäœãã®å Žåãå®çšçã§ãª
ãããã®æå³ãã奜ãŸããå¹³åååŸã¯100â«ã
5000â«ã®ç¯å²ã§ããããã奜ãŸããã¯200â«ã
3000â«ã®ç¯å²ã§ãããå¹³åååŸã®æž¬å®ã¯æ°Žéå§å ¥
åŒããã·ã¡ãŒã¿ã«ããã®ãè¯ãããã®æ¹æ³ã¯å€å
äœã«æ°Žéãå§å ¥ããŠè¡ããäŸµå ¥ããæ°Žééããæ°
åéããå§å ¥ã«èŠããå§åããååŸãæ±ãããã®
ã§ããã ãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã¯ããã®è¡šé¢ã«ãª
ãã·ã©ã³åºãæããŠãããåŸè¿°ããããã«ããã®
ãªãã·ã©ã³åºãè€çŽ ç°åŒååç©ãããŒãºè¡šé¢ã«åº
å®ããèœåãæããŠããããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã«ããããªãã·ã©ã³åºã®å«æéã¯ãããªãµ
ã«ããšãŒãæ³ïŒR.AxenïŒas quoted by â
Sundberg and âPorath in ïŒ
ChromatgraphyïŒ90ïŒ1974ïŒïŒ89ïŒã§æž¬å®ããå Ž
åã«800ã1000ÎŒmolïŒïœâdryã®ç¯å²ãæãŸããã 次ã«ãäžèšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã«çµå
ãããè€çŽ ç°åŒååç©ã«ã€ããŠèª¬æãããè€çŽ ç°
åŒååç©ãšã¯ãç°äžã«ççŽ ååãšå ±ã«çªçŽ ãé ž
çŽ ãç¡«é»çã®ãããååãå«ãææ©ååç©ã§ãè€
çŽ ç°ãšããŠã¯ïŒå¡ç°ãŸãã¯ïŒå¡ç°ãå€ãããã®äŸ
ãæããã°æ¬¡ã®éãã§ãããå³ã¡ããã©ã³ãšãã®
èªå°äœããã€ããšã³ãšãã®èªå°äœããã³ãžããªã©
ã³èªå°äœããããŒã«ãšãã®èªå°äœãã¢ãŸãŒã«é¡ã
ããªãžã³ãšãã®èªå°äœããããªã³ãšãã®é¢é£åå
ç©ãã¢ã¯ãªãžã³ãšãã®é¢é£ååç©ãããªãžã³ãšã
ã®é¢é£ååç©ããã©ãžã³ãšãã®é¢é£ååç©ããã©
ã³åã³ããã³ãšãã®é¢é£ååç©ãããšãããµãž
ã³ãããšããã¢ãžã³ããããªã³åã³ã¢ãããµãžã³
ååç©ãããªã³å¡©åºãæ žé žãããã³ãã¯ãããã€
ã«ããã¿ãã³B12ããã¿ãã·ã¢ãã³ãã¢ã«ã«ãã€
ããçž®åç°ç³»è€çŽ ç°åŒååç©çã§ããããããå€
æ°ã®è€çŽ ç°åŒååç©ã®äžã§ãããµã«ãã¢å€ãšããŠ
ç¥ãããã¹ã«ãã³ã¢ããé¡ïŒè€çŽ ç°ãæãããã®
ã«éãïŒãšãã®èªå°äœãããã³ã«ãããŒã«ã奜ãŸ
ããçµæãäžããããŸãããµã«ãã¢å€ã®äžã§ã¯ã¹
ã«ãã¢ãã¢ãŸãŒã«ãçã«å¥œãŸããçµæãäžããã äžèšã®è€çŽ ç°åŒååç©ã¯ãåèšãªãã·ã©ã³âã¢
ã¯ãªã«ããŒãºã®è¡šé¢ã«ååšãããªãã·ã©ã³åºã«çµ
åããããäž¡è éã®çµå圢æäœçœ®ã¯ãè€çŽ ç°åŒå
åç©ã®è€çŽ ç°ä»¥å€ã®ååãšããªãã·ã©ã³åºãæ§æ
ããäžæ¹ã®ççŽ ååãšã®éã§ããããã®åœ¢æ ã¯å ±
æçµåã§ããããã®çµåã®åœ¢æã«ã¯ãªãã·ã©ã³ã®
éç°ã䌎ãããªãã·ã©ã³åºã圢æããŠããé žçŽ å
åã¯æ°Žé žåºã«ãªã€ãŠçµåããã第ïŒå³ã¯ãäžèšã®
ããã«ããŠã¹ã«ãã¢ãã¢ãŸãŒã«ãçµåãããããª
ã€ããŒã®ãããã®è¡šé¢ã瀺ããŠãããå³äžç Žç·
ã§å²ãã éšåã¯éç°ãããªãã·ã©ã³åºã瀺ããŠã
ãããŸããã®å Žåã¯å³ç€ºã®ããã«ã¹ã«ãã¢ãã¢ãŸ
ãŒã«ã®ã¢ããªã³çªçŽ ããªãã·ã©ã³ççŽ ã«çµåããŠ
ããããªãã·ã©ã³åºã®éç°ã䌎ãäžèšã®çµå圢æ
åå¿ã¯æ¯èŒç容æã§ãããç¹ã«ãè€çŽ ç°åŒååç©
ã«æ°Žé žåºãã¢ããåºãããªãŒã«åºãã«ã«ããã«åº
ãå«ãå Žåã«ã¯ãåºãPHåã«ãããŠåå¿ãããã
ãšãå¯èœã§ããããçªçŽ ååãŸãã¯é žçŽ ååãšãª
ãã·ã©ã³ççŽ ååãšã®éã«çµåãçããããããš
ãã§ããããããããã®å Žåã®åå¿ã¯å®€æž©ïŒ21ã
25âïŒã«ãããŠ16ã72æéã§çµäºããããäžãã
åç¡ŒçŽ ãšãŒãã©ãŒããããšããŒã«ãããªãŠã ãã
ãªãšãã«ã¢ãã³ãããªãžã³çã®è§Šåªãçšããã°å
å¿é床ãæŽã«å éã§ããã 次ã«ãäžèšã®ããã«ããŠåŸãããæ¬çºæã®äœæ¶²
æååé¢æã«ã€ããŠèª¬æããããã®äžã€ã®ç¹åŸŽ
ã¯ãäžæº¶æ§æ äœãšããŠçšãããªãã·ã©ã³âã¢ã¯ãª
ã«ããŒãºãšããªã¬ã³ããšããŠçšããè€çŽ ç°åŒåå
ç©ãšããäžèšã®ããã«å ±æçµåãä»ããŠåŒ·åºã«çµ
åãããŠããç¹ã«ããããªã¬ã³ããäžæº¶æ§æ äœè¡š
é¢ã«åºå®ããæ¹æ³ãšããŠã¯ãå ±æçµå以å€ã«ãã€
ãªã³çµåãç©çåžçãå åãæ äœè¡šé¢ãžã®æ²æŸ±äž
溶åçãäžè¬ã«è¡ãªãããŠããããå ±æçµå以å€
ã®æ¹æ³ã§åºå®ããå Žåã«ã¯äœæ¶²äžã§ãªã¬ã³ããè±
é¢ãæããå®å®æ§ã«æ¬ ããããã®ãããäŸãã°äœ
å€åŸªç°äœæ¶²æµåçæ³ã«çšããå Žåããªã¬ã³ããè¡
液äžã«æ··å ¥ããŠå¯äœçšãçããçã®é倧ãªåé¡ã
çãããããã«å¯Ÿããæ¬çºæã®äœæ¶²æååé¢æã¯
äžèšã®ããã«ãªã¬ã³ãã匷åºã«äžæº¶æ§æ äœã«çµå
ãããŠå®å®ã§ããããããã®ãããªåé¡ã¯çããª
ãã æ¬çºæã«ããäœæ¶²æååé¢æã®æã倧ããªç¹åŸŽ
ã¯ãåŸè¿°ããå®æœäŸã®çµæã«ç€ºãããããã«ãæ¢
è¿°ããåé¢å €è±¡ç©è³ªã«å¯ŸããŠé«å¹çãäžã€é«ãç¹
ç°æ§ããã€ãåžçèœåãæããç¹ã«ããããã®ç¹
城ã¯ãªã¬ã³ãã«çšããåŸ©çŽ ç°åŒååç©ã®å¯äžã®ã¿
ãªãããæ äœãšããŠçšãããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã«ããå¯äžãšã®çµåãã«ãã€ãŠå§ããŠåŸã
ãããã®ã§ããã äžè¬ã«ãçæ°Žæ§ååç©ã ãã§æ§æãããåžç
æãå³ã¡çæ°Žçµåæ§ã®åŒ·ãåžçæã«ã¯äœæ¶²äžã®ã¢
ã«ããã³åç»çãé€å»å¯Ÿè±¡ä»¥å€ã®æçšãªèçœè³ªã
å€ãä»çãããããç å ç©è³ªã®éžæçé€å»ã«ã¯é©
ããªããéã«æ°ŽçŽ çµåæ§ã®åŒ·ã芪氎æ§ååç©ãæ
ãã¯éé»çµåæ§ã®åŒ·ãè·é»åºãå€ãæããååç©
ã§æ§æãããåžçæã§ã¯ãèçœè³ªã®ä»çéãèã
ãäœãããç å ç©è³ªãåžçã§ããªããåŸã€ãŠãäœ
液äžã®ç å ç©è³ªãåé¢ããã«ã¯çš®ã ã®çžäºäœçšå
ãé©åºŠã«çµåãã€ãåžçæã奜é©ãšãªãããã®èŠ³
ç¹ããæ¬çºæã®äœæ¶²æååé¢æãæ€èšããã°æ¬¡ã®
éãã§ããã ãŸããåèšè€çŽ ç°åŒååç©ã®ãããååïŒç¬¬ïŒ
å³ã®äŸã§ã¯ãã¢ãŸãŒã«ç°ã®çªçŽ ååããã³ç¡«é»å
åïŒã¯æå€æ®»è»éã«å€ç«é»å察ãæãããããã
ããã³ã¢ã¯ã»ãã¿ãŒãšããŠåããšå ±ã«ã解é¢åºã®
å°ãªãè€çŽ ç°ã¯çæ°Žæ§ã瀺ãããŸãè€çŽ ç°åŒåå
ç©ã®ãã¡ããµã«ãã¢å€ã®ã¹ã«ãã³ã¢ããéšåãã«
ãããŒã«ã®ã«ã«ããã«åºããã³ã€ããåºã¯æ°ŽçŽ çµ
åæ§ãæããŠãããä»æ¹ãè€çŽ ç°åŒååç©ãçµå
ããã¢ã¯ãªã«ããŒãºã¯ãé«ååççŽ éã®è¡šé¢ã«ç
æ°Žæ§ã瀺ãã¡ãã«åºãšãæ°ŽçŽ çµåæ§ã瀺ãé žã¢ã
ãåºãæããŠãããæŽã«ããªãã·ã©ã³åºã®éç°ã§
圢æãããæ°Žé žåºã¯èŠªæ°Žæ§ã瀺ãããããã®èŠçŽ
ã«ãã€ãŠãæ¬çºæã®åé¢æã¯ç å ç©è³ªã®ã¢ããé ž
æ®åºãšã®éã«çæ°Žæ§çµåãéé»çµåãæ°ŽçŽ çµåã®
çµåãã€ãçžäºäœçšãçãããŸãåèšè€çŽ ç°åŒå
åç©éšåãç å ç©è³ªã®ååå éãã«é©åºŠã«åµã蟌
ãããã奜ãŸããçµæãåŸããããã®ãšè§£éãã
ãã 次ã«ãæ¬çºæã®äœæ¶²æååé¢è£ 眮ã«ã€ããŠèª¬æ
ããã æ¬çºæã®åé¢è£ 眮ã¯ãæ¢è¿°ããããã«äœæ¶²ã®å°
å ¥å£ããã³å°åºå£ãæãã容åšå ã«ãäžèšã®äœæ¶²
æååé¢æãå å¡«ä¿æãããã®ã§ããã容åšã®æ
質ãšããŠã¯ã¬ã©ã¹ãã¹ãã³ã¬ã¹ãããªãšãã¬ã³ã
ããªãããã¬ã³ãããªã«ãŒãããŒããããªã¹ãã¬
ã³ãããªã¡ãã«ã¡ã¿ã¯ãªã¬ãŒãçã䜿çšã§ãã
ãããªãŒãã¯ã¬ãŒãæ» èãå¯èœã§åæ±ãæãããª
ãããã¬ã³ãããªã«ãŒãããŒãçãç¹ã«å¥œãŸã
ãããŸãã容åšæ¬äœã®åºå ¥å£éšãšåé¢æå±€ãšã®é
ã«ãäœæ¶²ã¯ééãããåé¢æã¯ééã§ããªã網ç®
ããã€ãã€ã«ã¿ãŒãåããŠãããã®ã奜ãŸããã
該ãã€ã«ã¿ãŒã®æ質ã¯ãççåŠçã«äžæŽ»æ§ã§åŒ·åºŠ
ã®é«ããã®ã§ããã°è¯ãããç¹ã«ããªãšã¹ãã«
補ãããªã¢ãã補ã®ãã®ã奜ãŸãã䜿çšãããã 第ïŒå³ã¯ãæ¬çºæã«ããäœæ¶²æååé¢è£ 眮ã®äž
å®æœäŸã瀺ãæé¢å³ã§ãããäœæ¶²ã¯å°å ¥å£ïŒãã
å°å ¥ãããäœæ¶²æååé¢æïŒã§åžçåŠçããã
åŸãå°åºå£ïŒããå°åºããããåé¢æã¯ãã€ã«ã¿
ãŒïŒïŒïŒâ²ã«ããã«ã©ã å ã«ä¿æãããŠããã äžèšæ¬çºæã®è£ 眮ãäœå€åŸªç°äœæ¶²æµåçæ³ã«é©
çšããå Žåã«ã¯ãäºéãã®æ¹æ³ãããã第äžã¯ã
äœå ããååºããè¡æ¶²ãè¡æŒ¿æåãšè¡çæåãšã«
åé¢ããåŸãè¡æŒ¿æåã®ã¿ãäžèšåé¢è£ 眮ã§æµå
åŠçããåŸãè¡çæåãšåãããŠäœå ã«æ»ãæ¹æ³
ã§ããããã®å Žåãè¡çïŒè¡æŒ¿ã®åé¢ã«ã¯é å¿å
é¢æ©ããŸãã¯èåãããã¯äžç©ºç³žåè¡æŒ¿åé¢æ©ã
çšããããã第äºã®æ¹æ³ã¯ãäœå ããååºããè¡
液ãäžèšè£ 眮å ã«çŽæ¥ééãããŠæµåããæ¹æ³ã§
ããããã®ãã¡ãåè ã®æ¹æ³ã«é©çšããäžäŸã第
ïŒå³ã«ç€ºãããã®å Žåãè¡æ¶²ã¯è¡æ¶²å°å ¥å£ïŒãã
å°å ¥ããããã³ãïŒãéã€ãŠè¡æŒ¿åé¢è£ 眮ïŒãžäŸ
絊ãããè¡çãšè¡æŒ¿ã«åé¢ããããåé¢ãããè¡
挿ã¯ãã³ãïŒâ²ãéã€ãŠæ¬çºæã«ä¿ãäœæ¶²æåå
é¢è£ 眮ïŒã«äŸçµŠãããåžçåŠçãããåŸã«è¡æŒ¿ïŒ
è¡çæ··åè£ çœ®ïŒã§è¡çãšæ··åãããŠè¡æ¶²å°åºå£ïŒ
ïŒããå°åºãããããªããäœæ¶²ã®åŸªç°æ¹æ³ãšããŠ
ã¯ãèšåºäžã®å¿ èŠããã³èšåã®ç¶æ³ã«å¿ããé£ç¶
çã«è¡ãªã€ãŠãããããŸãæç¶çã«è¡ãªã€ãŠãã
ãã 以äžãå®æœäŸã«åŸã€ãŠæŽã«è©³çŽ°ã«èª¬æããã å®æœäŸ ïŒ ãŸããæ¿åºŠ0.2molïŒã®çé žãããã¢ãŒïŒPH
10ïŒãšãžã¡ãã«ãã«ã ã¢ããã®æ··å液ïŒå®¹éæ¯
ïŒïŒïŒïŒ100mläžã«ãæ¿åºŠ0.1molïŒã«ãªããã
ã«ã¹ã«ãã¢ãã¢ãŸãŒã«æº¶è§£ããã該溶液äžã«ãªã
ã·ã©ã³âã¢ã¯ãªã«ããŒãºïŒïŒ²ïœÂšhm Pharma瀟補
ããªã€ããŒã®ãããïŒæ¶æ©æ§ã¢ãããŒã®æ¯çã¯30
ééïŒ ïŒã0.1ã0.2ïœïŒmlã®å²åã§æå ¥ããè±æ°
ããåŸã«è§ŠåªãšããŠããªâïœâããã«ã¢ãã³åã³
ããªãžã³1.0mlãæ·»å ãããããã80âã®æ°ŽæµŽäž
ã§ïŒæéå æž©ããåŸã«ããã©ãããããµãŒïŒè±å£
å»çç§å·¥æ¥è£œã®BMâ101åïŒã䜿çšããŠå®€æž©ã§
äžæ©æ¹æããã次ãã§ãæªåå¿ã®ãªãã·ã©ã³åºã
é€å»ããããã«æ¿åºŠ1molïŒïŒPHïŒïŒã®ãšã¿ã
ãŒã«ã¢ãã³æº¶æ¶²100mlãæ·»å ããäžæ©æ¹æããã
ãã®åŸãèžæºæ°Žãå¡©åãããªãŠã 0.5molãå«ã
æ¿åºŠ0.02molïŒïŒPHïŒïŒã®é ¢é žãããã¢ãŒæº¶
液ãæ¿åºŠ0.2molïŒïŒPH10ïŒã®çé žãããã¢ãŒ
溶液ã§é 次æŽæµãããããããåŸãããåžçæã
ãŒãºã¯ã第ïŒå³ã«ç€ºããããã«ã¹ã«ãã¢ãã¢ãŸãŒ
ã«ã®ã¢ããªã³çªçŽ ãããªã€ããŒããããã®ãªã
ã·ã©ã³åºãéç°ãããŠçµåãããã®ãšæšå®ãã
ãã äžèšã§åŸãããåžçæããŒãºïŒïœãã¬ã©ã¹è£œè©Š
éšç®¡å ïŒãã«ã¢ç€Ÿè£œãã©ã«ããïŒã«ç§€éããäžèš
ã®åžçå®éšã«äŸããã åžçå®éšã«éããŠã¯ããŸãäžèšåžçæãåçŽã
ãè©Šéšç®¡ã«ãå¡©åãããªãŠã 137mmolããã³å¡©
åã«ãªãŠã 2.6mmolãå«ãæ¿åºŠ8mmolïŒPH7.2ïŒã®
çé žãããã¢ãŒæº¶æ¶²ïŒPBSïŒãïŒmlå ¥ããã¢ã¹
ãã¬ãŒã¿ïŒæ±äº¬çååšæ©è£œãâ2SãïŒã§è±æ°ã
ãã次ã«ãæååºå€ãšããŠãããªã³6IUïŒmlãã
ã³ACDâ液50ÎŒlïŒmlãæ·»å ãããŠã·ã®è¡æŒ¿ïŒ
mlãå ãããã©ãããããµãŒãçšããŠæ¹æããªã
ãã37âã®ç±é¢šåŸªç°åŒæ枩槜ã§90åéã€ã³ããŠã
ãŒãããããšã«ããåžçåŠçãè¡ãªã€ãããã®
åŸã次ã®æ¹æ³ã«ããã¢ã«ããã³ïŒAlb.ïŒãã°ãã
ãªã³ïŒGlob.ïŒãå ç«ã°ãããªã³ïŒ§ïŒIgGïŒã®åžç
éã枬å®ããã å³ã¡ã容éïŒmlã®ãã«ã¢æ ªåŒäŒç€Ÿè£œãã€ã¹ããŒ
ã¶ãã«ã·ãªã³ãžãå©çšããŠäœæããããã«ã©ã å
ã«ãPBS1mlãçšããŠäžèšè©Šéšç®¡å 容ç©ã移ãã
åŸãPBS5mlã§ã«ã©ã ãæŽæµããŠæµåºæ¶²ãæéã
ãããã®æµåºæ¶²éã枬å®ããåŸããã®äžã«å«ãŸã
ãAlb.éããã³ç·èçœè³ªïŒProt.ïŒã®éã«ã€ããŠã
倫ã ããã ã¯ã¬ãŸãŒã«ã°ãªãŒã³ïŒBCGïŒæ³ãã
ãŠã¬ããæ³ã§æž¬å®ããããŸããGlob.éã¯Prot.é
Alb.éãšã®å·®ãšããŠæ±ãããå³ã¡ããã€ããªããŒ
ã²ã³ã䟿å®äžGlob.ã«å«ããŠèšç®ããããããšã¯
å¥ã«ãåžçæãçšããªãã§äžèšãšåæ§ã®æäœãè¡
ãªãããã®å Žåã®æµåºæ¶²ã«ã€ããŠåŸãããAlb.ã®
éãGlob.ã®éãåèšå€«ã ã®å€ããå·®åŒãããšã«
ããåžçéãç®åºãããããã®å€ã§åèšã®å€ãé€
ãããšã«ãã倫ã ã®åžççãèšç®ããã ãŸããåèšæµåºæ¶²äžã®IgGã®éãäžå æŸå°å ç«
æ¡æ£æ³ïŒSRIDïŒã«ãŠæž¬å®ããäžèšãšåæ§ã«ããŠ
IgGã®åžçéããã³åžççãæ±ããã äžèšã®åžçå®éšã®çµæã第ïŒè¡šã«ç€ºãã å®æœäŸ ïŒ å®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢ãŸãŒã«æº¶æ¶²ã®ä»£
ãã«ãæ¿åºŠ0.1mmolïŒã®ã«ãããŒã«æº¶æ¶²ãçš
ãããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåžçæ
ã調補ããã åŸãããåžçæãçšããå®æœäŸïŒã®å Žåãšåæ§
ã®åžçå®éšãè¡ãªã€ãããã®çµæã第ïŒè¡šã«ç€º
ãã å®æœäŸ ïŒ å®æœäŸïŒã§çšããããªã€ããŒã®ãããïŒæ¶æ©
æ§ã¢ãããŒã®å²åã30ééïŒ ïŒã®ä»£ãã«ãæ¶æ©æ§
ã¢ãããŒïŒïŒ®ïŒNâ²âã¡ãã¬ã³âãã¹âã¢ã¯ãªã«
ã¢ããïŒã®å²åãïŒééïŒ ã€ã§ããã¢ãããŒæ··å
ç©ããéåããããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã
çšããããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåž
çæã調補ããã åŸãããåžçæïŒïœãçšããå®æœäŸïŒãšåæ§ã®
åžçå®éšãè¡ãªã€ãçµæã第ïŒè¡šã«ç€ºãã å®æœäŸ ïŒ ã¹ã«ãã¢ãã¢ãŸãŒã«ã®ä»£ãã«ã«ãããŒã«ãçš
ãããã以å€ã¯å®æœäŸïŒãšåæ§ã«è¡ãªã€ããåŸã
ããåžçæã«ããå®æœäŸïŒãšåæ§ã®åžçè©Šéšã®çµ
æã第ïŒè¡šã«ç€ºãã æ¯èŒäŸ ïŒ å®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢ãŸãŒã«æº¶æ¶²ã®ä»£
ãã«ãæ¿åºŠ0.1mmolïŒã®ããšãã«ã¢ã©ãã³æº¶æ¶²
ãçšãããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåž
çæã調補ããã åŸãããåžçæãçšããå®æœäŸïŒã®å Žåãšåæ§
ã®åžçå®éšãè¡ãªã€ãããã®çµæã第ïŒè¡šã«ç€º
ãã æ¯èŒäŸ ïŒãïŒ ãããã®æ¯èŒäŸã§ã¯ãå®æœäŸïŒã§çšãããªãã·
ã©ã³âã¢ã¯ãªã«ããŒãºã®ä»£ãã«ãâãããããµ
ã¯ã·ã³ã€ãã掻æ§ãšã¹ãã«âã¢ã¬ããŒã¹ããŒãº
ïŒBioâRad瀟補ãAffiâGelâ10ãïŒãçšããã ãŸããæ¯èŒäŸïŒã§ã¯å®æœäŸïŒã«ããããšåã
ããæ¿åºŠ0.1mmolïŒã®ã¹ã«ãã¢ãã¢ãŸãŒã«æº¶æ¶²
ãçšãããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåž
çæã調補ããã æ¯èŒäŸïŒã§ã¯ãå®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢
ãŸãŒã«æº¶æ¶²ã®ä»£ãã«ãæ¿åºŠ0.1mmolïŒã®ã«ãã
ãŒã«æº¶æ¶²ãçšãããã以å€ã¯å®æœäŸïŒãšå šãåæ§
ã«ããŠåžçæã調補ããã æ¯èŒäŸïŒã§ã¯ãå®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢
ãŸãŒã«æº¶æ¶²ã®ä»£ãã«ãæ¿åºŠ0.1mmolïŒã®ããšã
ã«ã¢ã©ãã³æº¶æ¶²ãçšãããã以å€ã¯å®æœäŸïŒãšå š
ãåæ§ã«ããŠåžçæã調補ããã äžèšã®æ¯èŒäŸïŒãïŒã§åŸããã倫ã ã®åžçæã
çšããå®æœäŸïŒã®å Žåãšåæ§ã®åžçå®éšãè¡ãªã€
ãçµæã第ïŒè¡šã«ç€ºãã æ¯èŒäŸ ïŒãïŒ ãããã®æ¯èŒäŸã§ã¯ãå®æœäŸïŒã§çšãããªãã·
ã©ã³âã¢ã¯ãªã«ããŒãºã®ä»£ãã«ããªãã·ã©ã³âã
ãªã¹ãã¬ã³ããŒãºïŒäžè±åæ瀟補ãEXâ438ãïŒ
ãçšããã ãŸãè€çŽ ç°åŒååç©ãšããŠãæ¯èŒäŸïŒã§ã¯ã¹ã«
ãã¢ãã¢ãŸãŒã«ãæ¯èŒäŸïŒã§ã¯ã¹ã«ãã¢ã¡ãã¢ãŸ
ãŒã«ãæ¯èŒäŸïŒã§ã¯ã¹ã«ãã¢ãœã¡ãŸãŒã«ãæ¯èŒäŸ
ïŒã§ã¯ã«ãããŒã«ãçšããã ãã以å€ã¯å®æœäŸïŒãšåæ§ã«è¡ãªã€ããåŸãã
ãåžçæã«ã€ããŠã®åžçå®éšã®çµæã第ïŒè¡šã«ç€º
ãã æ¯èŒäŸ ïŒ ã¢ã¯ãªã«ã¢ãããšãïŒNâ²âã¡ãã¬ã³âãã¹
âã¢ã¯ãªã«ã¢ãããšã®å ±éåã«ãã補é ãããã
ãªã¢ã¯ãªã«ã¢ããããŒãºïŒBioâRad瀟補ãBio
âGel â300ãïŒèšæœ€æç²åŸ100ã200ã¡ãã·ãŠã
åç»ååéç¯å²ïŒäžã40äžã30mlïŒïœâdryïŒã
äžæº¶æ§æ äœã«çšããããã®ããªã¢ã¯ãªã«ã¢ããã
ãŒãºåŽéã®ã¢ããåºããççŽ å¡©ã§ãã¢ãããŒã·ãš
ã³ããŠã«ã«ããã·ã«åºã«è»¢åããåŸããã®ã«ã«ã
ãã·ã«åºã«å¯ŸããŠäžèšã®è€çŽ ç°åŒååç©ãè±æ°Žçž®
åã«ããçµåãããããã®éã氎溶æ§ã«ã«ããžã€
ããã¡ãã§ããïŒâã·ã¯ãããã·ã«âïŒâïŒïŒâ
ã¢ã«ããªããšãã«ïŒã«ã«ããžã€ããïœâãã«ãšã³
ã¹ã«ãããŒããè±æ°Žçž®åå€ãšããŠçšããã ã¹ã«ãã¢ãã¢ãŸãŒã«ïŒæ¯èŒäŸïŒïŒ ã«ãããŒã«ïŒæ¯èŒäŸ10ïŒ ããšãã«ã¢ã©ãã³ïŒæ¯èŒäŸ11ïŒ äžèšã§åŸãããåžçæã«ã€ããŠã倫ã å®æœäŸïŒ
ã®å Žåãšåãåžçå®éšãè¡ãªãã第ïŒè¡šã«ç€ºãçµ
æãåŸãã
åé¢ããäœæ¶²æååé¢æãšããããçšããäœæ¶²æ
ååé¢è£ 眮ã«é¢ããã ïŒå è¡æè¡ããã³ãã®åé¡ç¹ïŒ è¿å¹Žãäœæ¶²äžã®ç¹å®æåãé節ãªçç¶ãæ¹èµ·ã
ãçŸæ£ã®æ²»çæ³ãšããŠãè¡æŒ¿äº€æçæ³ãè¡ãªãã
ãŠããããã®çæ³ã¯ç å ç©è³ªã®éæãå°é£ãªå Žå
ã«ç¹ã«å¹æçã§ãéççç¡åçãé¢ç¯ãªãŠããã
çŽ ææ§çŒç¡çã®èªå·±å ç«çŸæ£ã糞çäœè çãæ°ç®¡
æ¯åæ¯ãå€çºæ§ç¥çµççã®å ç«é¢é£çŸæ£ãèåšç§»
æ€ã«äŒŽãæ絶åå¿ãèäžå šãé«è¡å§ãççŸæ£ãã
ã®ä»ã«å¯ŸããŠé©çšãããŠããããã®ãã¡èªå·±å ç«
çŸæ£ãšã¯ãèªå·±ã®çŽ°èãçµç¹ã®ãã€æåã«å¯ŸããŠ
äœæ¶²æ§ãããã¯çŽ°èæ§ã®å ç«å¿çããããããã
ã«ãã€ãŠåœ¢æãããèªå·±ã«å¯Ÿããæäœãåå ãšãª
ã€ãŠçºçããçŸæ£ãããã ããããè¡æŒ¿äº€æçæ³ã¯è¡æŒ¿æåã®å šãŠãç¡å·®
å¥ã«é€å»ãããããç å ç©è³ªä»¥å€ã«è¡æŒ¿ã®æçšæ
åããåªå€±ããŠããŸãåé¡ããããå ããŠãè£å
液ãšããŠã®è¡æŒ¿ãè¡æŒ¿è£œå€ã®äžè¶³ãè¡æž èçãã¢
ã¬ã«ã®ãŒçã®å䜵ãšãã€ãå€ãã®åé¡ãææãã
ãŠããããããããèªå·±ã®è¡æŒ¿ãæµåããåŸã«å
茞泚ããæ¹æ³ãå³ã¡ãäœå€åŸªç°æ¶²æµåçæ³ãæãŸ
ãããšãããŠããããã®å Žåãèªå·±ã®è¡æ¶²ããç
å ç©è³ªãå åäžã€éžæçã«é€å»ããæ²»çç®çãé
æãããšå ±ã«äœèçœè¡çãé²æ¢ããããšãå¿ èŠ
ã§ããã®ããã®æµåæãšããŠåŸæ¥æ¬¡ã®ãããªåžç
æãç¥ãããŠããã ã» å€åæ§æš¹èïŒäŸãã°RošhmïŒHaas瀟補ã®å
ååãã¢ã³ããŒã©ã€ãXADâïŒãç ã» ã€ãªã³äº€æäœïŒäŸãã°ã«ã«ããã·ã¡ãã«ã»ã«
ããŒã¹ããžãšãã«ã¢ãããšãã«ã¢ã¬ããŒã¹çïŒ ã» ç¡æ©å€åäœïŒäŸãã°å€å質ã¬ã«ã¹ãã»ã©ãã
ã¯çïŒ ã» ã¢ãã€ããã€ãŒåžçæ ããããå€åæ§æš¹èãã€ãªã³äº€æäœã¯åžçèœã
å°ããããããåžçç¹ç°æ§ãäœãããäœæ¶²äžã®ã¢
ã«ããã³ããåžçããããã®çµæããããè¡æ¶²æµ
åæãšããŠåèšçæ³ã«é©çšãããšæ²»çå¹æãäžå
åãªã§ã ãã§ãªããäœèçœè¡çã«ç¹æã®æµžéå§ç°
åžžãæ¥ãããŠæµ®è «ãçããçãå®å šæ§ã«åé¡ãã
ãããŸããç¡æ©å€åäœã¯åžçèœãåžçç¹æ§ã«ã€ã
ãŠã¯æ¯èŒçè¯å¥œã§ããããæªã å®çšçã«ã¯äžåå
ã§ããã ããã«å¯Ÿããã¢ãã€ããã€ãŒåžçæã¯åªããåž
çèœããã³åžçç¹ç°æ§ãæããè¡æ¶²æµåæãšããŠ
ææèŠãããŠããããã®ã¿ã€ãã®åžçæã¯ãã®åž
çäœçšã®çžéãããçç©åŠçã¢ãã€ããã€ãŒåžç
æãšç©çååŠçã¢ãã€ããã€ãŒåžçæãšã«åé¡ã
ãããã®äžè¬çç¹åŸŽãšãã®åé¡ç¹ã説æããã°æ¬¡
ã®éãã§ããã ãŸãçç©åŠçã¢ãã€ããã€ãŒåžçæã¯æåæäœ
çµåãè£äœçµåãFcçµåçã®çç©åŠççžäºäœçš
ã§è¡æ¶²äžã®ç å ç©è³ªãšçµåãããããåžçããã
ã®ã§ãåžçç¹ç°æ§ã«æ¥µããŠåªããŠããããããã
ãã®å€ãã¯DNAãæLDLæäœããããã€ã³ïŒ¡ç
ã®çç掻æ§é«ååããªã¬ã³ãïŒç®çãšããç å ç©
質ãšèŠªåæ§ããã€ç©è³ªïŒãšããŠçšãããããåæ
ãé«äŸ¡ã§äžã€ç¢ºä¿ãå°é£ã§ããåé¡ãããããŸ
ãããªã¬ã³ãã®å®å®æ§ãä¹ãããããåžçæãã
ããå å¡«ããã«ã©ã ã®è£œé ãæ» èã貯èµãéæ¬ã
ä¿ç®¡ã«éããŠæŽ»æ§ãä¿æããã®ãé£ãããå ã
ãŠããªã¬ã³ããæ¬æ¥çã«çç掻æ§ç©è³ªã§ããã
ãããããè¡æ¶²ãšæ¥è§Šããå Žåã«ææã®èŠªååã
çºæ®ããã«æ¢ãŸãããæ¬æ¥ã®ççäœçšãçºçŸããŠ
å¯äœçšãçããããšãèæ ®ããªããã°ãªããªãã
ãããããªã¬ã³ãã¯ç°çš®èçœã§ãããããããã
åžçææ äœããéé¢ããŠæº¶åºããå Žåããã®æå
æ§ã«ããå¯äœçšãçºçããããšã«ãªãã ããã«å¯Ÿããç©çååŠçã¢ãã€ããã€ãŒåžçæ
ã¯éé»çµåãçæ°Žçµåçãç©ççãŸãã¯ååŠççž
äºäœçšã§è¡æ¶²äžã®ç å ç©è³ªãšçµåãããããåžç
åé¢ããŠé€å»ãããã®ã§ããããã®å Žåã®ãªã¬ã³
ããšããŠã¯ããªãªãžã³ãã¡ãã«åã¢ã«ããã³ãã
ãªãããã¢ã³ãããšãã«ã¢ã©ãã³çã®åæç©ãçš
ããããšãã§ããããã®ãã倧é補é ãå¯èœã§äŸ¡
æ Œãæ¯èŒçå®ãã掻æ§ãå®å®ã§ããå©ç¹ãæããŠ
ããããŸãè¡æ¶²ãšæ¥è§Šããå Žåã®å®å šæ§ã«ã€ããŠ
ãäžè¬ã«åªãããã®ãå€ããããåèšçŸæ£æ²»çã®
ããã®äœå€åŸªç°äœæ¶²æµåçæ³ã«çšããæµåæãšã
ãŠæãæåŸ ãããããŠãããæŽã«ããã®äœçšãã
ã³äŸ¡æ ŒããããŠãäžèšçæ³ã®ããã®è¡æ¶²æµåæãš
ããŠã®ã¿ãªãããå ç«ã°ãããªã³ãå ç«è€åäœã
ãã³å ç«é¢é£å¯æº¶æ§å åçã®äœæ¶²ç¹å®æåã®åé¢
粟補ããŸãã¯ãããæåã®æ€æ»ã«ãçšéãæåŸ ã
ããããã®åé¡ã«å±ããåžçæã§åŸæ¥ç¥ãããŠã
ããã®ãæããã°æ¬¡ã®éãã§ããã ã«ã«ããã·ã«åºãŸãã¯ã¹ã«ãã³é žåºãè¡šé¢ã«
æããå€åäœïŒç¹éæ56â147710ãå57â
56038ãå57â75141ãå57â170263ãå57â
197294ïŒ çæ°Žæ§ã¢ããé žãçµåãããŠãã芪氎æ§æ äœ
ïŒç¹éæ57â122875ãå58â15924ãå58â
165859ãå58â165861ïŒ å€æ§å ç«ã°ãããªã³ïŒlgGïŒãçµåãããŠã
ã芪氎æ§æ äœïŒç¹éæ57â77624ãå57â
77625ãå57â156035ïŒ ã¡ãã«åã¢ã«ããã³ãçµåãããŠããå€åäœ
ïŒç¹éæ55â120875ãå55â125872ïŒ ç³ãçµåãããŠãã芪氎æ§æ äœïŒç¹éæ57â
134164ãå58â133257ïŒ ããªã³å¡©åºãŸãã¯ããªããžã³å¡©åºãæãã¯ç³
çé žãçµåãããŠããå€åäœïŒç¹éæ57â
192560ãå58â61752ãå58â98142ïŒ ãããããããåŸæ¥ã®ç©çååŠçã¢ãã€ããã€
ãŒåžçæããåèšäœå€åŸªç°æ¶²æµåçæ³ã«ããèªå·±
å ç«çŸæ£çã®æ²»çã«ã¯æªã å åãšã¯ããããæŽã«
é«ãå¹çããã³ç¹ç°æ§ã§ç å ç©è³ªãé€å»ããããš
ãã§ãããŸãäœæ¶²ã«å¯Ÿããæªåœ±é¿ã®å°ãªãæµåæ
ãæãŸããŠããã çºæã®ç®ç æ¬çºæã¯äžèšäºæ ã«éã¿ãŠãªããããã®ã§ãã
ã®ç®çã¯è¡æ¶²ããªã³ã液ãè ¹æ°Žçã®äœæ¶²äžã«å«ãŸ
ããç¹å®æåãé«å¹çãã€é«ãç¹ç°æ§ã§åžçåé¢
ã§ãããšå ±ã«ã掻æ§ãå®å®ã§æ» èæäœãä¿ç®¡ã容
æãªäœæ¶²æååé¢æã䞊ã³ã«ãããçšããäœæ¶²æ
ååé¢è£ 眮ãæäŸããããšã§ããã æ¬çºæã®ç¬¬äžã®ç®çã§ããäœæ¶²æååé¢æã¯ã
ãªãã·ã©ã³åºãæããäžé£œåã®ã©ãžã«ã«éåæ§ã¢
ãããŒåã³æ¶æ©æ§ã¢ãããŒãå«ãã¢ãããŒæ··åç©
ãéåããŠåŸãã¢ã¯ãªã«ç³»ããªããŒã®ãã¡ããªã
ã·ã©ã³åºå«æéã也ç¥ééïŒïœåœã0.1ã10mmol
ã§ãããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã«ãè€çŽ ç°åŒ
ååç©ãçµåãããããšã«ãã€ãŠåŸãããããã®
éãåèšè€çŽ ç°åŒååç©ã®è€çŽ ç°ä»¥å€ã®ååãå
èšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºè¡šé¢ã«é²åºãããª
ãã·ã©ã³åºãæ§æããäžæ¹ã®ççŽ ã«å ±æçµåãã
ããšå ±ã«ãåèšãªãã·ã©ã³åºã¯éç°ããããã®é ž
çŽ ååã¯æ°Žé žåºãšããŠä»æ¹ã®ççŽ ååã«å ±æçµå
ãããããšã«ãªãã æ¬çºæã®ç¬¬äºã®ç®çã§ããäœæ¶²æååé¢è£ 眮
ã¯ãçžäºã«é£éããäœæ¶²å°å ¥å£ããã³äœæ¶²å°åºå£
ãæãã容åšå ã«ãäžèšã®äœæ¶²æååé¢æãå å¡«
ããããšã«ãã€ãŠåŸããããå¿ èŠã«å¿ããäœæ¶²åŸª
ç°ãã³ãçã®èŠçŽ ãä»å ããã æ¬çºæã¯èªå·±å ç«çŸæ£çã®æ²»çãç®çãšããäœ
å€åŸªç°äœæ¶²æµåçæ³ã«ãããŠãç¹ã«å¥œé©ã«çšãã
ããšãã§ããã çºæã®å ·äœç説æ æ¬çºæã®äœæ¶²æååé¢æã¯ãæ¢è¿°ããç©çååŠ
çã¢ãã€ããã€ãŒåžçæã«å±ããããã®å¯Ÿè±¡ãšã
ã被åžçç©è³ªã¯äœæ¶²äžã®èçœè³ªã§ãããããã詳
现ã«èª¬æããã°æ¬¡ã®éãã§ãããå³ã¡ãéåžžã®å
ç«ã°ãããªã³ïŒïŒ¡ïŒïŒ€ïŒïŒ¥ïŒïŒ§ïŒïŒïŒãåçš®èªå·±
æäœãå ç«ã°ãããªã³çžäºéãŸãã¯å ç«ã°ãããª
ã³ãšä»ã®ç©è³ªïŒç¹ã«æäœïŒãšã®è€åç©ãè£äœãã
ã€ããªããŒã²ã³ãå¯æº¶æ§ãã€ããªã³ãäœå¯åºŠãªã
ãããã€ã³ãç现èå¢æ®å åãå ç«é¢é£å¯æº¶æ§å
åïŒIRAïŒlmmunoâregulatory αâglobulinïŒ
ã»ã«æé·å åïŒTCGFïŒïŒŽâcell growth
factorïŒãGSFïŒGrowth soluble factorïŒãSSF
ïŒSuppresor soluble factorïŒãTRFïŒïŒŽâcell
replacing factorïŒãKHFïŒKiller cell helper
factorïŒãLSFïŒLymphocyteâstimulating
factorïŒãCIFïŒCompetenceâinducing factorïŒã
TDFïŒThymocytoâdiffer entiation factorïŒã
ã€ã³ã¿ãŒãã€ãã³çã§ããããã®ãã¡ãèªå·±æ
äœã®äŸãšããŠã¯ã现èè¡šé¢æäœãèå£çŽ°èãã¯ã
ãŸãŒã æäœãå¯è ç®è³ªçŽ°å¯è³ªæäœçã®èåšç¹ç°å
ïŒç¬¬çŸ€ïŒãã¢ã»ãã«ã³ãªã³ã¬ã»ãã¿ãŒã«å¯Ÿããæ
äœãèµ€è¡çæäœãå¹³æ¡æ»çæäœãã€ã³ã·ãŠãªã³ã¬
ã»ãã¿ãŒæäœçã®äžéåïŒç¬¬çŸ€ïŒãDNAæäœã
ååºå åæäœãææ žæäœãælgGæäœçã®èåšé
ç¹ç°åïŒç¬¬çŸ€ïŒãæããããããªããæ¬çºæã«
ãããåé¢å¯Ÿè±¡ã§ãããããç å èçœç©è³ªã¯ãäœ
ããäœæ¶²èçœåç»ã®ãã¡ã®ã°ãããªã³åç»ã«å«ãŸ
ããŠããã æ¬çºæã®äœæ¶²æååé¢æã¯ãªãã·ã©ã³âã¢ã¯ãª
ã«ããŒãºãäžæº¶æ§æ äœãšãããã®è¡šé¢ã«è€çŽ ç°åŒ
ååç©ãçµåãããã®ã§ãããããã§äžæº¶æ§æ
äœãè€çŽ ç°åŒååç©ããã³ãããã®çµåæ¹æ³çã«
ã€ããŠå€«ã 説æããã äžæº¶æ§æ äœãšããŠçšãããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã¯ãã¡ã¿ã¯ãªã«é žã°ãªã·ãžã«ãŸãã¯ã¢ãªã«
ã°ãªã·ãžã«ãšãŒãã«ãã¡ã¿ã¯ãªã«ã¢ãããã¡ãã¬
ã³âãã¹âã¡ã¿ã¯ãªã«ã¢ããã®å ±éåã«ããåŸã
ããããã®è£œæ³ã¯ããŒã ã»ãã¢ã«ã瀟ïŒRošhm
PharmaïŒã«ããé瀺ãããŠããïŒè±åœç¹èš±ç¬¬
1329062å·ããã€ãåœç¹èš±å ¬å第2237316å·ããã€
ãåœç¹èš±ç¬¬2263289å·ïŒããã®ãªãã·ã©ã³âã¢ã¯ãª
ã«ããŒãºã®å ãæ¬çºæã«ãããäžæº¶æ§æ äœãšããŠ
ç¹ã«å¥œé©ã«çšãããããã®ã¯ãæ¶æ©æ§ã¢ãããŒã®
æ¯çãïŒééïŒ ä»¥äžããªãã·ã©ã³åºãæããã©ãž
ã«ã«éåæ§ã¢ãããŒã®æ¯çãïŒã60ééïŒ ã®ã¢ã
ããŒæ··åç©ããåŸããããã®ã§ããããã®ããã«
ç¹ã«å¥œãŸãããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã®äŸãš
ããŠã¯ãããŒã ã»ãã¢ã«ã瀟ããããªã€ããŒã®ã
ããã®åååã§æäŸãããŠãããã®ãæããã
ããããã¯ãåœå ã«ãããŠæšå£åäŒã«ããèŒžå ¥è²©
売ãããŠããã äžèšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã®åœ¢ç¶ã¯çŽ°è
ã«æå·ãäžããããŸãç ããæ¬ ããçãé£ããã
ã«ç圢ãšãããŠãããå¹³åç²åŸã¯ãäœæ¶²ã®æµéã
æµéå§åãèæ ®ãã0.05mmãïŒmmã®ç¯å²ã奜ãŸã
ãã¯0.1mmã0.2mmã®ç¯å²ã®ãã®ãçšãããããå¹³
åç²åŸãæ±ããã«ã¯JISââ8801ã«èŠå®ãããŠ
ãã篩ãçšããŠåçŽããåŸãåçŽã«ã€ããŠã¯äžé
ç²åŸãšäžéç²åŸã®äžéå€ãåœè©²çŽã®ç²åŸãšããã
ããã®ééå¹³åãšããŠå šäœã®å¹³åç²åŸãç®åºã
ãã ãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã¯ãç å ç©è³ªãé«
ãå¹çã§åžçé€å»ããããã«è¡šé¢ç©ã®å€§ããå€å
äœã§ããããšã奜ãŸããããŸãã該å€åäœã®å¹³å
ååŸãå°ãéãããšåžçãããç å ç©è³ªã®éãå°
ãªãã倧ãéãããšå€åäœã®åŒ·åºŠãäœäžãäžã€è¡š
é¢ç©ãæžå°ãããããäœãã®å Žåãå®çšçã§ãª
ãããã®æå³ãã奜ãŸããå¹³åååŸã¯100â«ã
5000â«ã®ç¯å²ã§ããããã奜ãŸããã¯200â«ã
3000â«ã®ç¯å²ã§ãããå¹³åååŸã®æž¬å®ã¯æ°Žéå§å ¥
åŒããã·ã¡ãŒã¿ã«ããã®ãè¯ãããã®æ¹æ³ã¯å€å
äœã«æ°Žéãå§å ¥ããŠè¡ããäŸµå ¥ããæ°Žééããæ°
åéããå§å ¥ã«èŠããå§åããååŸãæ±ãããã®
ã§ããã ãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã¯ããã®è¡šé¢ã«ãª
ãã·ã©ã³åºãæããŠãããåŸè¿°ããããã«ããã®
ãªãã·ã©ã³åºãè€çŽ ç°åŒååç©ãããŒãºè¡šé¢ã«åº
å®ããèœåãæããŠããããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã«ããããªãã·ã©ã³åºã®å«æéã¯ãããªãµ
ã«ããšãŒãæ³ïŒR.AxenïŒas quoted by â
Sundberg and âPorath in ïŒ
ChromatgraphyïŒ90ïŒ1974ïŒïŒ89ïŒã§æž¬å®ããå Ž
åã«800ã1000ÎŒmolïŒïœâdryã®ç¯å²ãæãŸããã 次ã«ãäžèšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã«çµå
ãããè€çŽ ç°åŒååç©ã«ã€ããŠèª¬æãããè€çŽ ç°
åŒååç©ãšã¯ãç°äžã«ççŽ ååãšå ±ã«çªçŽ ãé ž
çŽ ãç¡«é»çã®ãããååãå«ãææ©ååç©ã§ãè€
çŽ ç°ãšããŠã¯ïŒå¡ç°ãŸãã¯ïŒå¡ç°ãå€ãããã®äŸ
ãæããã°æ¬¡ã®éãã§ãããå³ã¡ããã©ã³ãšãã®
èªå°äœããã€ããšã³ãšãã®èªå°äœããã³ãžããªã©
ã³èªå°äœããããŒã«ãšãã®èªå°äœãã¢ãŸãŒã«é¡ã
ããªãžã³ãšãã®èªå°äœããããªã³ãšãã®é¢é£åå
ç©ãã¢ã¯ãªãžã³ãšãã®é¢é£ååç©ãããªãžã³ãšã
ã®é¢é£ååç©ããã©ãžã³ãšãã®é¢é£ååç©ããã©
ã³åã³ããã³ãšãã®é¢é£ååç©ãããšãããµãž
ã³ãããšããã¢ãžã³ããããªã³åã³ã¢ãããµãžã³
ååç©ãããªã³å¡©åºãæ žé žãããã³ãã¯ãããã€
ã«ããã¿ãã³B12ããã¿ãã·ã¢ãã³ãã¢ã«ã«ãã€
ããçž®åç°ç³»è€çŽ ç°åŒååç©çã§ããããããå€
æ°ã®è€çŽ ç°åŒååç©ã®äžã§ãããµã«ãã¢å€ãšããŠ
ç¥ãããã¹ã«ãã³ã¢ããé¡ïŒè€çŽ ç°ãæãããã®
ã«éãïŒãšãã®èªå°äœãããã³ã«ãããŒã«ã奜ãŸ
ããçµæãäžããããŸãããµã«ãã¢å€ã®äžã§ã¯ã¹
ã«ãã¢ãã¢ãŸãŒã«ãçã«å¥œãŸããçµæãäžããã äžèšã®è€çŽ ç°åŒååç©ã¯ãåèšãªãã·ã©ã³âã¢
ã¯ãªã«ããŒãºã®è¡šé¢ã«ååšãããªãã·ã©ã³åºã«çµ
åããããäž¡è éã®çµå圢æäœçœ®ã¯ãè€çŽ ç°åŒå
åç©ã®è€çŽ ç°ä»¥å€ã®ååãšããªãã·ã©ã³åºãæ§æ
ããäžæ¹ã®ççŽ ååãšã®éã§ããããã®åœ¢æ ã¯å ±
æçµåã§ããããã®çµåã®åœ¢æã«ã¯ãªãã·ã©ã³ã®
éç°ã䌎ãããªãã·ã©ã³åºã圢æããŠããé žçŽ å
åã¯æ°Žé žåºã«ãªã€ãŠçµåããã第ïŒå³ã¯ãäžèšã®
ããã«ããŠã¹ã«ãã¢ãã¢ãŸãŒã«ãçµåãããããª
ã€ããŒã®ãããã®è¡šé¢ã瀺ããŠãããå³äžç Žç·
ã§å²ãã éšåã¯éç°ãããªãã·ã©ã³åºã瀺ããŠã
ãããŸããã®å Žåã¯å³ç€ºã®ããã«ã¹ã«ãã¢ãã¢ãŸ
ãŒã«ã®ã¢ããªã³çªçŽ ããªãã·ã©ã³ççŽ ã«çµåããŠ
ããããªãã·ã©ã³åºã®éç°ã䌎ãäžèšã®çµå圢æ
åå¿ã¯æ¯èŒç容æã§ãããç¹ã«ãè€çŽ ç°åŒååç©
ã«æ°Žé žåºãã¢ããåºãããªãŒã«åºãã«ã«ããã«åº
ãå«ãå Žåã«ã¯ãåºãPHåã«ãããŠåå¿ãããã
ãšãå¯èœã§ããããçªçŽ ååãŸãã¯é žçŽ ååãšãª
ãã·ã©ã³ççŽ ååãšã®éã«çµåãçããããããš
ãã§ããããããããã®å Žåã®åå¿ã¯å®€æž©ïŒ21ã
25âïŒã«ãããŠ16ã72æéã§çµäºããããäžãã
åç¡ŒçŽ ãšãŒãã©ãŒããããšããŒã«ãããªãŠã ãã
ãªãšãã«ã¢ãã³ãããªãžã³çã®è§Šåªãçšããã°å
å¿é床ãæŽã«å éã§ããã 次ã«ãäžèšã®ããã«ããŠåŸãããæ¬çºæã®äœæ¶²
æååé¢æã«ã€ããŠèª¬æããããã®äžã€ã®ç¹åŸŽ
ã¯ãäžæº¶æ§æ äœãšããŠçšãããªãã·ã©ã³âã¢ã¯ãª
ã«ããŒãºãšããªã¬ã³ããšããŠçšããè€çŽ ç°åŒåå
ç©ãšããäžèšã®ããã«å ±æçµåãä»ããŠåŒ·åºã«çµ
åãããŠããç¹ã«ããããªã¬ã³ããäžæº¶æ§æ äœè¡š
é¢ã«åºå®ããæ¹æ³ãšããŠã¯ãå ±æçµå以å€ã«ãã€
ãªã³çµåãç©çåžçãå åãæ äœè¡šé¢ãžã®æ²æŸ±äž
溶åçãäžè¬ã«è¡ãªãããŠããããå ±æçµå以å€
ã®æ¹æ³ã§åºå®ããå Žåã«ã¯äœæ¶²äžã§ãªã¬ã³ããè±
é¢ãæããå®å®æ§ã«æ¬ ããããã®ãããäŸãã°äœ
å€åŸªç°äœæ¶²æµåçæ³ã«çšããå Žåããªã¬ã³ããè¡
液äžã«æ··å ¥ããŠå¯äœçšãçããçã®é倧ãªåé¡ã
çãããããã«å¯Ÿããæ¬çºæã®äœæ¶²æååé¢æã¯
äžèšã®ããã«ãªã¬ã³ãã匷åºã«äžæº¶æ§æ äœã«çµå
ãããŠå®å®ã§ããããããã®ãããªåé¡ã¯çããª
ãã æ¬çºæã«ããäœæ¶²æååé¢æã®æã倧ããªç¹åŸŽ
ã¯ãåŸè¿°ããå®æœäŸã®çµæã«ç€ºãããããã«ãæ¢
è¿°ããåé¢å €è±¡ç©è³ªã«å¯ŸããŠé«å¹çãäžã€é«ãç¹
ç°æ§ããã€ãåžçèœåãæããç¹ã«ããããã®ç¹
城ã¯ãªã¬ã³ãã«çšããåŸ©çŽ ç°åŒååç©ã®å¯äžã®ã¿
ãªãããæ äœãšããŠçšãããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã«ããå¯äžãšã®çµåãã«ãã€ãŠå§ããŠåŸã
ãããã®ã§ããã äžè¬ã«ãçæ°Žæ§ååç©ã ãã§æ§æãããåžç
æãå³ã¡çæ°Žçµåæ§ã®åŒ·ãåžçæã«ã¯äœæ¶²äžã®ã¢
ã«ããã³åç»çãé€å»å¯Ÿè±¡ä»¥å€ã®æçšãªèçœè³ªã
å€ãä»çãããããç å ç©è³ªã®éžæçé€å»ã«ã¯é©
ããªããéã«æ°ŽçŽ çµåæ§ã®åŒ·ã芪氎æ§ååç©ãæ
ãã¯éé»çµåæ§ã®åŒ·ãè·é»åºãå€ãæããååç©
ã§æ§æãããåžçæã§ã¯ãèçœè³ªã®ä»çéãèã
ãäœãããç å ç©è³ªãåžçã§ããªããåŸã€ãŠãäœ
液äžã®ç å ç©è³ªãåé¢ããã«ã¯çš®ã ã®çžäºäœçšå
ãé©åºŠã«çµåãã€ãåžçæã奜é©ãšãªãããã®èŠ³
ç¹ããæ¬çºæã®äœæ¶²æååé¢æãæ€èšããã°æ¬¡ã®
éãã§ããã ãŸããåèšè€çŽ ç°åŒååç©ã®ãããååïŒç¬¬ïŒ
å³ã®äŸã§ã¯ãã¢ãŸãŒã«ç°ã®çªçŽ ååããã³ç¡«é»å
åïŒã¯æå€æ®»è»éã«å€ç«é»å察ãæãããããã
ããã³ã¢ã¯ã»ãã¿ãŒãšããŠåããšå ±ã«ã解é¢åºã®
å°ãªãè€çŽ ç°ã¯çæ°Žæ§ã瀺ãããŸãè€çŽ ç°åŒåå
ç©ã®ãã¡ããµã«ãã¢å€ã®ã¹ã«ãã³ã¢ããéšåãã«
ãããŒã«ã®ã«ã«ããã«åºããã³ã€ããåºã¯æ°ŽçŽ çµ
åæ§ãæããŠãããä»æ¹ãè€çŽ ç°åŒååç©ãçµå
ããã¢ã¯ãªã«ããŒãºã¯ãé«ååççŽ éã®è¡šé¢ã«ç
æ°Žæ§ã瀺ãã¡ãã«åºãšãæ°ŽçŽ çµåæ§ã瀺ãé žã¢ã
ãåºãæããŠãããæŽã«ããªãã·ã©ã³åºã®éç°ã§
圢æãããæ°Žé žåºã¯èŠªæ°Žæ§ã瀺ãããããã®èŠçŽ
ã«ãã€ãŠãæ¬çºæã®åé¢æã¯ç å ç©è³ªã®ã¢ããé ž
æ®åºãšã®éã«çæ°Žæ§çµåãéé»çµåãæ°ŽçŽ çµåã®
çµåãã€ãçžäºäœçšãçãããŸãåèšè€çŽ ç°åŒå
åç©éšåãç å ç©è³ªã®ååå éãã«é©åºŠã«åµã蟌
ãããã奜ãŸããçµæãåŸããããã®ãšè§£éãã
ãã 次ã«ãæ¬çºæã®äœæ¶²æååé¢è£ 眮ã«ã€ããŠèª¬æ
ããã æ¬çºæã®åé¢è£ 眮ã¯ãæ¢è¿°ããããã«äœæ¶²ã®å°
å ¥å£ããã³å°åºå£ãæãã容åšå ã«ãäžèšã®äœæ¶²
æååé¢æãå å¡«ä¿æãããã®ã§ããã容åšã®æ
質ãšããŠã¯ã¬ã©ã¹ãã¹ãã³ã¬ã¹ãããªãšãã¬ã³ã
ããªãããã¬ã³ãããªã«ãŒãããŒããããªã¹ãã¬
ã³ãããªã¡ãã«ã¡ã¿ã¯ãªã¬ãŒãçã䜿çšã§ãã
ãããªãŒãã¯ã¬ãŒãæ» èãå¯èœã§åæ±ãæãããª
ãããã¬ã³ãããªã«ãŒãããŒãçãç¹ã«å¥œãŸã
ãããŸãã容åšæ¬äœã®åºå ¥å£éšãšåé¢æå±€ãšã®é
ã«ãäœæ¶²ã¯ééãããåé¢æã¯ééã§ããªã網ç®
ããã€ãã€ã«ã¿ãŒãåããŠãããã®ã奜ãŸããã
該ãã€ã«ã¿ãŒã®æ質ã¯ãççåŠçã«äžæŽ»æ§ã§åŒ·åºŠ
ã®é«ããã®ã§ããã°è¯ãããç¹ã«ããªãšã¹ãã«
補ãããªã¢ãã補ã®ãã®ã奜ãŸãã䜿çšãããã 第ïŒå³ã¯ãæ¬çºæã«ããäœæ¶²æååé¢è£ 眮ã®äž
å®æœäŸã瀺ãæé¢å³ã§ãããäœæ¶²ã¯å°å ¥å£ïŒãã
å°å ¥ãããäœæ¶²æååé¢æïŒã§åžçåŠçããã
åŸãå°åºå£ïŒããå°åºããããåé¢æã¯ãã€ã«ã¿
ãŒïŒïŒïŒâ²ã«ããã«ã©ã å ã«ä¿æãããŠããã äžèšæ¬çºæã®è£ 眮ãäœå€åŸªç°äœæ¶²æµåçæ³ã«é©
çšããå Žåã«ã¯ãäºéãã®æ¹æ³ãããã第äžã¯ã
äœå ããååºããè¡æ¶²ãè¡æŒ¿æåãšè¡çæåãšã«
åé¢ããåŸãè¡æŒ¿æåã®ã¿ãäžèšåé¢è£ 眮ã§æµå
åŠçããåŸãè¡çæåãšåãããŠäœå ã«æ»ãæ¹æ³
ã§ããããã®å Žåãè¡çïŒè¡æŒ¿ã®åé¢ã«ã¯é å¿å
é¢æ©ããŸãã¯èåãããã¯äžç©ºç³žåè¡æŒ¿åé¢æ©ã
çšããããã第äºã®æ¹æ³ã¯ãäœå ããååºããè¡
液ãäžèšè£ 眮å ã«çŽæ¥ééãããŠæµåããæ¹æ³ã§
ããããã®ãã¡ãåè ã®æ¹æ³ã«é©çšããäžäŸã第
ïŒå³ã«ç€ºãããã®å Žåãè¡æ¶²ã¯è¡æ¶²å°å ¥å£ïŒãã
å°å ¥ããããã³ãïŒãéã€ãŠè¡æŒ¿åé¢è£ 眮ïŒãžäŸ
絊ãããè¡çãšè¡æŒ¿ã«åé¢ããããåé¢ãããè¡
挿ã¯ãã³ãïŒâ²ãéã€ãŠæ¬çºæã«ä¿ãäœæ¶²æåå
é¢è£ 眮ïŒã«äŸçµŠãããåžçåŠçãããåŸã«è¡æŒ¿ïŒ
è¡çæ··åè£ çœ®ïŒã§è¡çãšæ··åãããŠè¡æ¶²å°åºå£ïŒ
ïŒããå°åºãããããªããäœæ¶²ã®åŸªç°æ¹æ³ãšããŠ
ã¯ãèšåºäžã®å¿ èŠããã³èšåã®ç¶æ³ã«å¿ããé£ç¶
çã«è¡ãªã€ãŠãããããŸãæç¶çã«è¡ãªã€ãŠãã
ãã 以äžãå®æœäŸã«åŸã€ãŠæŽã«è©³çŽ°ã«èª¬æããã å®æœäŸ ïŒ ãŸããæ¿åºŠ0.2molïŒã®çé žãããã¢ãŒïŒPH
10ïŒãšãžã¡ãã«ãã«ã ã¢ããã®æ··å液ïŒå®¹éæ¯
ïŒïŒïŒïŒ100mläžã«ãæ¿åºŠ0.1molïŒã«ãªããã
ã«ã¹ã«ãã¢ãã¢ãŸãŒã«æº¶è§£ããã該溶液äžã«ãªã
ã·ã©ã³âã¢ã¯ãªã«ããŒãºïŒïŒ²ïœÂšhm Pharma瀟補
ããªã€ããŒã®ãããïŒæ¶æ©æ§ã¢ãããŒã®æ¯çã¯30
ééïŒ ïŒã0.1ã0.2ïœïŒmlã®å²åã§æå ¥ããè±æ°
ããåŸã«è§ŠåªãšããŠããªâïœâããã«ã¢ãã³åã³
ããªãžã³1.0mlãæ·»å ãããããã80âã®æ°ŽæµŽäž
ã§ïŒæéå æž©ããåŸã«ããã©ãããããµãŒïŒè±å£
å»çç§å·¥æ¥è£œã®BMâ101åïŒã䜿çšããŠå®€æž©ã§
äžæ©æ¹æããã次ãã§ãæªåå¿ã®ãªãã·ã©ã³åºã
é€å»ããããã«æ¿åºŠ1molïŒïŒPHïŒïŒã®ãšã¿ã
ãŒã«ã¢ãã³æº¶æ¶²100mlãæ·»å ããäžæ©æ¹æããã
ãã®åŸãèžæºæ°Žãå¡©åãããªãŠã 0.5molãå«ã
æ¿åºŠ0.02molïŒïŒPHïŒïŒã®é ¢é žãããã¢ãŒæº¶
液ãæ¿åºŠ0.2molïŒïŒPH10ïŒã®çé žãããã¢ãŒ
溶液ã§é 次æŽæµãããããããåŸãããåžçæã
ãŒãºã¯ã第ïŒå³ã«ç€ºããããã«ã¹ã«ãã¢ãã¢ãŸãŒ
ã«ã®ã¢ããªã³çªçŽ ãããªã€ããŒããããã®ãªã
ã·ã©ã³åºãéç°ãããŠçµåãããã®ãšæšå®ãã
ãã äžèšã§åŸãããåžçæããŒãºïŒïœãã¬ã©ã¹è£œè©Š
éšç®¡å ïŒãã«ã¢ç€Ÿè£œãã©ã«ããïŒã«ç§€éããäžèš
ã®åžçå®éšã«äŸããã åžçå®éšã«éããŠã¯ããŸãäžèšåžçæãåçŽã
ãè©Šéšç®¡ã«ãå¡©åãããªãŠã 137mmolããã³å¡©
åã«ãªãŠã 2.6mmolãå«ãæ¿åºŠ8mmolïŒPH7.2ïŒã®
çé žãããã¢ãŒæº¶æ¶²ïŒPBSïŒãïŒmlå ¥ããã¢ã¹
ãã¬ãŒã¿ïŒæ±äº¬çååšæ©è£œãâ2SãïŒã§è±æ°ã
ãã次ã«ãæååºå€ãšããŠãããªã³6IUïŒmlãã
ã³ACDâ液50ÎŒlïŒmlãæ·»å ãããŠã·ã®è¡æŒ¿ïŒ
mlãå ãããã©ãããããµãŒãçšããŠæ¹æããªã
ãã37âã®ç±é¢šåŸªç°åŒæ枩槜ã§90åéã€ã³ããŠã
ãŒãããããšã«ããåžçåŠçãè¡ãªã€ãããã®
åŸã次ã®æ¹æ³ã«ããã¢ã«ããã³ïŒAlb.ïŒãã°ãã
ãªã³ïŒGlob.ïŒãå ç«ã°ãããªã³ïŒ§ïŒIgGïŒã®åžç
éã枬å®ããã å³ã¡ã容éïŒmlã®ãã«ã¢æ ªåŒäŒç€Ÿè£œãã€ã¹ããŒ
ã¶ãã«ã·ãªã³ãžãå©çšããŠäœæããããã«ã©ã å
ã«ãPBS1mlãçšããŠäžèšè©Šéšç®¡å 容ç©ã移ãã
åŸãPBS5mlã§ã«ã©ã ãæŽæµããŠæµåºæ¶²ãæéã
ãããã®æµåºæ¶²éã枬å®ããåŸããã®äžã«å«ãŸã
ãAlb.éããã³ç·èçœè³ªïŒProt.ïŒã®éã«ã€ããŠã
倫ã ããã ã¯ã¬ãŸãŒã«ã°ãªãŒã³ïŒBCGïŒæ³ãã
ãŠã¬ããæ³ã§æž¬å®ããããŸããGlob.éã¯Prot.é
Alb.éãšã®å·®ãšããŠæ±ãããå³ã¡ããã€ããªããŒ
ã²ã³ã䟿å®äžGlob.ã«å«ããŠèšç®ããããããšã¯
å¥ã«ãåžçæãçšããªãã§äžèšãšåæ§ã®æäœãè¡
ãªãããã®å Žåã®æµåºæ¶²ã«ã€ããŠåŸãããAlb.ã®
éãGlob.ã®éãåèšå€«ã ã®å€ããå·®åŒãããšã«
ããåžçéãç®åºãããããã®å€ã§åèšã®å€ãé€
ãããšã«ãã倫ã ã®åžççãèšç®ããã ãŸããåèšæµåºæ¶²äžã®IgGã®éãäžå æŸå°å ç«
æ¡æ£æ³ïŒSRIDïŒã«ãŠæž¬å®ããäžèšãšåæ§ã«ããŠ
IgGã®åžçéããã³åžççãæ±ããã äžèšã®åžçå®éšã®çµæã第ïŒè¡šã«ç€ºãã å®æœäŸ ïŒ å®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢ãŸãŒã«æº¶æ¶²ã®ä»£
ãã«ãæ¿åºŠ0.1mmolïŒã®ã«ãããŒã«æº¶æ¶²ãçš
ãããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåžçæ
ã調補ããã åŸãããåžçæãçšããå®æœäŸïŒã®å Žåãšåæ§
ã®åžçå®éšãè¡ãªã€ãããã®çµæã第ïŒè¡šã«ç€º
ãã å®æœäŸ ïŒ å®æœäŸïŒã§çšããããªã€ããŒã®ãããïŒæ¶æ©
æ§ã¢ãããŒã®å²åã30ééïŒ ïŒã®ä»£ãã«ãæ¶æ©æ§
ã¢ãããŒïŒïŒ®ïŒNâ²âã¡ãã¬ã³âãã¹âã¢ã¯ãªã«
ã¢ããïŒã®å²åãïŒééïŒ ã€ã§ããã¢ãããŒæ··å
ç©ããéåããããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã
çšããããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåž
çæã調補ããã åŸãããåžçæïŒïœãçšããå®æœäŸïŒãšåæ§ã®
åžçå®éšãè¡ãªã€ãçµæã第ïŒè¡šã«ç€ºãã å®æœäŸ ïŒ ã¹ã«ãã¢ãã¢ãŸãŒã«ã®ä»£ãã«ã«ãããŒã«ãçš
ãããã以å€ã¯å®æœäŸïŒãšåæ§ã«è¡ãªã€ããåŸã
ããåžçæã«ããå®æœäŸïŒãšåæ§ã®åžçè©Šéšã®çµ
æã第ïŒè¡šã«ç€ºãã æ¯èŒäŸ ïŒ å®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢ãŸãŒã«æº¶æ¶²ã®ä»£
ãã«ãæ¿åºŠ0.1mmolïŒã®ããšãã«ã¢ã©ãã³æº¶æ¶²
ãçšãããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåž
çæã調補ããã åŸãããåžçæãçšããå®æœäŸïŒã®å Žåãšåæ§
ã®åžçå®éšãè¡ãªã€ãããã®çµæã第ïŒè¡šã«ç€º
ãã æ¯èŒäŸ ïŒãïŒ ãããã®æ¯èŒäŸã§ã¯ãå®æœäŸïŒã§çšãããªãã·
ã©ã³âã¢ã¯ãªã«ããŒãºã®ä»£ãã«ãâãããããµ
ã¯ã·ã³ã€ãã掻æ§ãšã¹ãã«âã¢ã¬ããŒã¹ããŒãº
ïŒBioâRad瀟補ãAffiâGelâ10ãïŒãçšããã ãŸããæ¯èŒäŸïŒã§ã¯å®æœäŸïŒã«ããããšåã
ããæ¿åºŠ0.1mmolïŒã®ã¹ã«ãã¢ãã¢ãŸãŒã«æº¶æ¶²
ãçšãããã以å€ã¯å®æœäŸïŒãšå šãåæ§ã«ããŠåž
çæã調補ããã æ¯èŒäŸïŒã§ã¯ãå®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢
ãŸãŒã«æº¶æ¶²ã®ä»£ãã«ãæ¿åºŠ0.1mmolïŒã®ã«ãã
ãŒã«æº¶æ¶²ãçšãããã以å€ã¯å®æœäŸïŒãšå šãåæ§
ã«ããŠåžçæã調補ããã æ¯èŒäŸïŒã§ã¯ãå®æœäŸïŒã§çšããã¹ã«ãã¢ãã¢
ãŸãŒã«æº¶æ¶²ã®ä»£ãã«ãæ¿åºŠ0.1mmolïŒã®ããšã
ã«ã¢ã©ãã³æº¶æ¶²ãçšãããã以å€ã¯å®æœäŸïŒãšå š
ãåæ§ã«ããŠåžçæã調補ããã äžèšã®æ¯èŒäŸïŒãïŒã§åŸããã倫ã ã®åžçæã
çšããå®æœäŸïŒã®å Žåãšåæ§ã®åžçå®éšãè¡ãªã€
ãçµæã第ïŒè¡šã«ç€ºãã æ¯èŒäŸ ïŒãïŒ ãããã®æ¯èŒäŸã§ã¯ãå®æœäŸïŒã§çšãããªãã·
ã©ã³âã¢ã¯ãªã«ããŒãºã®ä»£ãã«ããªãã·ã©ã³âã
ãªã¹ãã¬ã³ããŒãºïŒäžè±åæ瀟補ãEXâ438ãïŒ
ãçšããã ãŸãè€çŽ ç°åŒååç©ãšããŠãæ¯èŒäŸïŒã§ã¯ã¹ã«
ãã¢ãã¢ãŸãŒã«ãæ¯èŒäŸïŒã§ã¯ã¹ã«ãã¢ã¡ãã¢ãŸ
ãŒã«ãæ¯èŒäŸïŒã§ã¯ã¹ã«ãã¢ãœã¡ãŸãŒã«ãæ¯èŒäŸ
ïŒã§ã¯ã«ãããŒã«ãçšããã ãã以å€ã¯å®æœäŸïŒãšåæ§ã«è¡ãªã€ããåŸãã
ãåžçæã«ã€ããŠã®åžçå®éšã®çµæã第ïŒè¡šã«ç€º
ãã æ¯èŒäŸ ïŒ ã¢ã¯ãªã«ã¢ãããšãïŒNâ²âã¡ãã¬ã³âãã¹
âã¢ã¯ãªã«ã¢ãããšã®å ±éåã«ãã補é ãããã
ãªã¢ã¯ãªã«ã¢ããããŒãºïŒBioâRad瀟補ãBio
âGel â300ãïŒèšæœ€æç²åŸ100ã200ã¡ãã·ãŠã
åç»ååéç¯å²ïŒäžã40äžã30mlïŒïœâdryïŒã
äžæº¶æ§æ äœã«çšããããã®ããªã¢ã¯ãªã«ã¢ããã
ãŒãºåŽéã®ã¢ããåºããççŽ å¡©ã§ãã¢ãããŒã·ãš
ã³ããŠã«ã«ããã·ã«åºã«è»¢åããåŸããã®ã«ã«ã
ãã·ã«åºã«å¯ŸããŠäžèšã®è€çŽ ç°åŒååç©ãè±æ°Žçž®
åã«ããçµåãããããã®éã氎溶æ§ã«ã«ããžã€
ããã¡ãã§ããïŒâã·ã¯ãããã·ã«âïŒâïŒïŒâ
ã¢ã«ããªããšãã«ïŒã«ã«ããžã€ããïœâãã«ãšã³
ã¹ã«ãããŒããè±æ°Žçž®åå€ãšããŠçšããã ã¹ã«ãã¢ãã¢ãŸãŒã«ïŒæ¯èŒäŸïŒïŒ ã«ãããŒã«ïŒæ¯èŒäŸ10ïŒ ããšãã«ã¢ã©ãã³ïŒæ¯èŒäŸ11ïŒ äžèšã§åŸãããåžçæã«ã€ããŠã倫ã å®æœäŸïŒ
ã®å Žåãšåãåžçå®éšãè¡ãªãã第ïŒè¡šã«ç€ºãçµ
æãåŸãã
ãè¡šã
ãè¡šã
çºæã®å
·äœçå¹æ
äžèšå®æœäŸããã³æ¯èŒäŸã«ãããåžçå®éšçµæ
ããæãããªããã«ãæ¬çºæã®äœæ¶²æååé¢æ
ã¯ãç å ç©è³ªã§ããå ç«ã°ãããªã³ãå ç«è€åäœ
ããã³å ç«é¢é£å¯æº¶æ§å åçã®èçœè³ªãå¹çãã€
é«ãéžææ§ã§åžçé€å»ããããšãå¯èœã§ããããŸ
ãããªã¬ã³ããäœååã®åæææ©ååç©ã§ããã
ããæ» èæäœã容æäžã€ç¢ºå®ã«è¡ãããšãã§ã
ããæŽã«ããã®æ§ææåã§ãããªãã·ã©ã³âã¢ã¯
ãªã«ããŒãºãè€çŽ ç°åŒååç©ã¯äœããæ¯æ§ãäœ
ããå®å šæ§ãé«ããå³ã¡ããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã®LD50å€ã¯ãã©ããã«ãããçµå£æäžã§
15ïœïŒKgãã倧ããããŸãè€çŽ ç°åŒååç©ã®ãã¡
ã¹ã«ãã¢ãŸãŒã«ã®LD50å€ã¯ããŠã¹ã«ãããéè
泚å°990mgïŒKgã§ããã ãããã®ç¹åŸŽãããæ¬çºæã®äœæ¶²æååé¢æã¯
äœæ¶²äžã®ç å ç©è³ªãåžçé€å»ããäœæ¶²ãæµåãã
ã®ã«æ¥µããŠé©ããŠãããäœå€åŸªç°äœæ¶²æµåçæ³ã«
ããèªå·±å ç«çŸæ£ãå ç«é¢é£çŸæ£çã®æ²»çã«å¹æ
çã§ããã ãŸããäžèšæ²»çç®çã®ã¿ãªããå ç«ã°ãããª
ã³ãå ç«è€åäœãããã³å ç«é¢é£å¯æº¶æ§å åçã®
èçœè³ªã®åé¢ã粟補çšããŸãã¯ãããç©è³ªã®æ€æ»
çšãšããŠãæå¹ã«å©çšã§ããã ä»æ¹ãæ¬çºæã®äœæ¶²æååé¢è£ 眮ã¯æ§é ãç°¡å
ã§ããããããããçšããããšã«ãããäžèšäœæ¶²
æååé¢æã«ããç å ç©è³ªã®åé¢ã粟補ãããã
ã¯äœæ¶²æµåã«ããåçš®çŸæ£ã®æ²»ççã容æã«è¡ãª
ãããšãã§ããã
ããæãããªããã«ãæ¬çºæã®äœæ¶²æååé¢æ
ã¯ãç å ç©è³ªã§ããå ç«ã°ãããªã³ãå ç«è€åäœ
ããã³å ç«é¢é£å¯æº¶æ§å åçã®èçœè³ªãå¹çãã€
é«ãéžææ§ã§åžçé€å»ããããšãå¯èœã§ããããŸ
ãããªã¬ã³ããäœååã®åæææ©ååç©ã§ããã
ããæ» èæäœã容æäžã€ç¢ºå®ã«è¡ãããšãã§ã
ããæŽã«ããã®æ§ææåã§ãããªãã·ã©ã³âã¢ã¯
ãªã«ããŒãºãè€çŽ ç°åŒååç©ã¯äœããæ¯æ§ãäœ
ããå®å šæ§ãé«ããå³ã¡ããªãã·ã©ã³âã¢ã¯ãªã«
ããŒãºã®LD50å€ã¯ãã©ããã«ãããçµå£æäžã§
15ïœïŒKgãã倧ããããŸãè€çŽ ç°åŒååç©ã®ãã¡
ã¹ã«ãã¢ãŸãŒã«ã®LD50å€ã¯ããŠã¹ã«ãããéè
泚å°990mgïŒKgã§ããã ãããã®ç¹åŸŽãããæ¬çºæã®äœæ¶²æååé¢æã¯
äœæ¶²äžã®ç å ç©è³ªãåžçé€å»ããäœæ¶²ãæµåãã
ã®ã«æ¥µããŠé©ããŠãããäœå€åŸªç°äœæ¶²æµåçæ³ã«
ããèªå·±å ç«çŸæ£ãå ç«é¢é£çŸæ£çã®æ²»çã«å¹æ
çã§ããã ãŸããäžèšæ²»çç®çã®ã¿ãªããå ç«ã°ãããª
ã³ãå ç«è€åäœãããã³å ç«é¢é£å¯æº¶æ§å åçã®
èçœè³ªã®åé¢ã粟補çšããŸãã¯ãããç©è³ªã®æ€æ»
çšãšããŠãæå¹ã«å©çšã§ããã ä»æ¹ãæ¬çºæã®äœæ¶²æååé¢è£ 眮ã¯æ§é ãç°¡å
ã§ããããããããçšããããšã«ãããäžèšäœæ¶²
æååé¢æã«ããç å ç©è³ªã®åé¢ã粟補ãããã
ã¯äœæ¶²æµåã«ããåçš®çŸæ£ã®æ²»ççã容æã«è¡ãª
ãããšãã§ããã
第ïŒå³ã¯ãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºè¡šé¢ã«ã¹
ã«ãã¢ãã¢ãŸãŒã«ãçµåãããç¶æ ã瀺ã説æ
å³ã第ïŒå³ã¯æ¬çºæã«ããäœæ¶²æååé¢è£ 眮ã®äž
å®æœäŸã瀺ãæé¢å³ã§ããã第ïŒå³ã¯ãããçšã
ãäœå€åŸªç°äœæ¶²æµåçæ³ã®äžäŸã瀺ããããŒãã€
ãŒãã§ããã ïŒâŠäœæ¶²æååé¢è£ 眮ãïŒâŠäœæ¶²æååé¢æã
ïŒïŒïŒâ²âŠãã€ã«ã¿ãŒãïŒâŠäœæ¶²å°å ¥å£ãïŒâŠäœ
液å°åºå£ãïŒâŠè¡æ¶²å°å ¥å£ãïŒïŒïŒâ²âŠãã³ãã
ïŒâŠè¡æŒ¿åé¢è£ 眮ãïŒâŠè¡æŒ¿ïŒè¡çæ··åè£ çœ®ãïŒ
ïŒâŠè¡æ¶²å°åºå£ã
ã«ãã¢ãã¢ãŸãŒã«ãçµåãããç¶æ ã瀺ã説æ
å³ã第ïŒå³ã¯æ¬çºæã«ããäœæ¶²æååé¢è£ 眮ã®äž
å®æœäŸã瀺ãæé¢å³ã§ããã第ïŒå³ã¯ãããçšã
ãäœå€åŸªç°äœæ¶²æµåçæ³ã®äžäŸã瀺ããããŒãã€
ãŒãã§ããã ïŒâŠäœæ¶²æååé¢è£ 眮ãïŒâŠäœæ¶²æååé¢æã
ïŒïŒïŒâ²âŠãã€ã«ã¿ãŒãïŒâŠäœæ¶²å°å ¥å£ãïŒâŠäœ
液å°åºå£ãïŒâŠè¡æ¶²å°å ¥å£ãïŒïŒïŒâ²âŠãã³ãã
ïŒâŠè¡æŒ¿åé¢è£ 眮ãïŒâŠè¡æŒ¿ïŒè¡çæ··åè£ çœ®ãïŒ
ïŒâŠè¡æ¶²å°åºå£ã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ãªãã·ã©ã³åºãæããäžé£œåã®ã©ãžã«ã«éå
æ§ã¢ãããŒåã³æ¶æ©æ§ã¢ãããŒãå«ãã¢ãããŒæ··
åç©ãéåããŠåŸãã¢ã¯ãªã«ç³»ããªããŒã®ãã¡ã
ãªãã·ã©ã³åºå«æéã也ç¥ééïŒïœåœã0.1ã
10mmolã§ãããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã«è€
çŽ ç°åŒååç©ãçµåãããäœæ¶²æååé¢æã§ãã€
ãŠãåèšè€çŽ ç°åŒååç©ã®è€çŽ ç°ä»¥å€ã®ååãå
èšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºè¡šé¢ã«é²åºãããª
ãã·ã©ã³åºãæ§æããäžæ¹ã®ççŽ ã«çµåããããš
å ±ã«ãåèšãªãã·ã©ã³åºã¯éç°ãããŠãã®é žçŽ å
åãæ°Žé žåºãšããŠä»æ¹ã®ççŽ ååã«çµåãããŠã
ãããšãç¹åŸŽãšããäœæ¶²æååé¢æã ïŒ åèšãªãã·ã©ã³åºãæããäžé£œåã®ã©ãžã«ã«
éåæ§ã¢ãããŒãïŒã60ééïŒ ãåèšæ¶æ©æ§ã¢ã
ããŒïŒééïŒ ä»¥äžã§ããããšãç¹åŸŽãšããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®äœæ¶²æååé¢æã ïŒ åèšè€çŽ ç°åŒååç©ããµã«ãã¢å€ãŸãã¯ãã®
èªå°äœãããã³ã«ãããŒã«ãããªã矀ããéžæã
ãããã®ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²
第ïŒé ãŸãã¯ïŒé èšèŒã®äœæ¶²æååé¢æã ïŒ ãªãã·ã©ã³åºãæããäžé£œåã®ã©ãžã«ã«éå
æ§ã¢ãããŒåã³æ¶æ©æ§ã¢ãããŒãå«ãã¢ãããŒæ··
åç©ãéåããŠåŸãã¢ã¯ãªã«ç³»ããªããŒã®ãã¡ã
ãªãã·ã©ã³åºå«æéã也ç¥ééïŒïœåœã0.1ã
10mmolã§ãããªãã·ã©ã³âã¢ã¯ãªã«ããŒãºã«è€
çŽ ç°åŒååç©ãçµåãããäœæ¶²æååé¢æã§ãã€
ãŠãåèšè€çŽ ç°åŒååç©ã®è€çŽ ç°ä»¥å€ã®ååãå
èšãªãã·ã©ã³âã¢ã¯ãªã«ããŒãºè¡šé¢ã«é²åºãããª
ãã·ã©ã³åºãæ§æããäžæ¹ã®ççŽ ã«çµåããããš
å ±ã«ãåèšãªãã·ã©ã³åºã¯éç°ãããŠãã®é žçŽ å
åãæ°Žé žåºãšããŠä»æ¹ã®ççŽ ååã«çµåãããŠã
ãäœæ¶²æååé¢æãã液äœå°å ¥å£ããã³æ¶²äœå°åº
å£ãæãã容åšå ã«åçŽããããšãç¹åŸŽãšããäœ
液æååé¢è£ 眮ã
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61152166A JPS639450A (ja) | 1986-06-28 | 1986-06-28 | äœæ¶²æååé¢æããã³ãããåããäœæ¶²æååé¢è£ 眮 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61152166A JPS639450A (ja) | 1986-06-28 | 1986-06-28 | äœæ¶²æååé¢æããã³ãããåããäœæ¶²æååé¢è£ 眮 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS639450A JPS639450A (ja) | 1988-01-16 |
| JPH0226988B2 true JPH0226988B2 (ja) | 1990-06-13 |
Family
ID=15534469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61152166A Granted JPS639450A (ja) | 1986-06-28 | 1986-06-28 | äœæ¶²æååé¢æããã³ãããåããäœæ¶²æååé¢è£ 眮 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS639450A (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0446287U (ja) * | 1990-08-27 | 1992-04-20 | ||
| JP2008237893A (ja) * | 2007-02-22 | 2008-10-09 | Toray Ind Inc | è¡æ¶²åŠçã«ã©ã |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0358758A1 (en) * | 1987-04-09 | 1990-03-21 | Terumo Kabushiki Kaisha | B lymphocyte separating material and body fluid clarifying material |
| SE0303532D0 (sv) | 2003-12-23 | 2003-12-23 | Amersham Biosciences Ab | Purification of immunoglobulins |
-
1986
- 1986-06-28 JP JP61152166A patent/JPS639450A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0446287U (ja) * | 1990-08-27 | 1992-04-20 | ||
| JP2008237893A (ja) * | 2007-02-22 | 2008-10-09 | Toray Ind Inc | è¡æ¶²åŠçã«ã©ã |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS639450A (ja) | 1988-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0171054B1 (en) | Body fluid purification medium and apparatus | |
| EP0056977B1 (en) | Immune adsorbent, adsorbing device and blood purifying apparatus | |
| EP0197521B1 (en) | Immunoglobulin adsorbent and adsorption apparatus | |
| JPH0226988B2 (ja) | ||
| JP2814399B2 (ja) | å šè¡åŠççšåžçåš | |
| JPH0114791B2 (ja) | ||
| JPH01181875A (ja) | å ç«è€åäœã®åžçäœããã³ãããçšããå ç«è€åäœã®é€å»è£ 眮 | |
| JPS59169532A (ja) | åå¿æ§èçœã®åžçæ | |
| JPS59186559A (ja) | èªå·±æäœããã³ïŒãŸãã¯å ç«è€åäœåžçæ | |
| JPS6253669A (ja) | å ç«ã°ãããªã³ç©è³ªã®åžçæããã³åžçè£ çœ® | |
| JPH01265972A (ja) | äœæ¶²äžã®æ害æåã®é€å»æ¹æ³ | |
| JPH0622632B2 (ja) | åžçäœããã³é€å»è£ 眮 | |
| JPH0771632B2 (ja) | åžçäœããã³ãããçšããé€å»è£ 眮 | |
| JPH01158970A (ja) | çŽæ¥è¡æ¶²æœ æµçšå ç«ã°ãããªã³åžçæããã³åžçè£ çœ® | |
| JPS6226073A (ja) | çŽæ¥è¡æ¶²æœ æµåžçæ¹æ³ããã³ãã®è£ 眮 | |
| JP2726662B2 (ja) | åžçäœããã³ãããçšããé€å»è£ 眮 | |
| JPS6125567A (ja) | å ç«ã°ãããªã³ã®åžçæããã³åžçè£ çœ® | |
| JPS59189859A (ja) | èªå·±æäœãå ç«è€åäœãåžçããææ | |
| JPH0233265B2 (ja) | ||
| JP3730386B2 (ja) | äœæ¶²åŠççšåžçäœãäœæ¶²åŠçæ¹æ³åã³äœæ¶²åŠçåš | |
| JP3251547B2 (ja) | å ç«è€åäœã®é€å»è£ 眮 | |
| JP3084436B2 (ja) | æïœïœïœæäœã®é€å»è£ 眮 | |
| JPS5917355A (ja) | å ç«åžçæ | |
| JPS59186560A (ja) | èªå·±æäœãå ç«è€åäœã®åžçæ | |
| JPH0611336B2 (ja) | äœæ¶²æµåæããã³äœæ¶²æµåè£ çœ® |